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APPENDIX: Original publications I-IV 
 
Abstract 
 
Catechol-O-methyltransferase (COMT) metabolises catecholamines such as dopamine, 
noradrenaline and adrenaline, which are well-characterised neurotransmitters that play 
important roles in the regulation of physiological processes. The COMT enzyme exists in 
membrane-bound (MB-COMT) and soluble (S-COMT) forms that are both encoded by 
the same gene. Presently, the necessity and physiological importance of the existence of 
two COMT isoenzymes remains partially unknown. The aim of this thesis was to provide 
new insights into the specific distribution patterns of MB-COMT and S-COMT, to verify 
the proposed hormonal regulation of COMT and to investigate its possible physiological 
role in feeding behaviour. 
 
We used two different study designs to address the distribution of COMT in the brain. 
First, we utilised dopaminergic and noradrenergic toxins to assess the presence of 
COMT in presynaptic neurons originating from selected brain areas. Successful lesioning 
of the neurons was confirmed by measuring dopamine and noradrenaline levels in their 
respective projection areas. However, despite successful lesioning, no changes in COMT 
protein expression or activity could be noted, indicating that COMT is not present in 
presynaptic dopaminergic and noradrenergic neurons. 
The specific distribution patterns of MB-COMT and S-COMT were studied in an 
S-COMT-deficient mouse line (lacking the S-COMT form of COMT). By comparing 
these mice to wild type mice, we found that the general distribution patterns of both 
COMT isoforms were similar between the genotypes. Notably, S-COMT-deficient mice 
did not exhibit nuclear COMT staining, indicating that MB-COMT is not present in cell 
nuclei. Furthermore, S-COMT-deficient mice allowed us to examine the association of 
MB-COMT with the plasma membrane. Contrary to previous assumptions, MB-COMT is 
not associated with the plasma membrane, but instead may be attached to intracellular 
cytosolic membranes. 
 
The proposed regulatory function of oestrogens on COMT activity was studied by 
subjecting male and female Wistar rats to different hormonal treatments over a two-week 
period. Antagonising/modulating the effects of oestrogen via the administration of 
tamoxifen increased COMT activity and expression. Unexpectedly, increasing oestradiol 
levels in male rats also led to the upregulation of COMT expression in several tissues, 
underscoring the importance of COMT in the clearance of biologically active oestrogen 
metabolites. 
 
Finally, we used female rodents (rats and mice) to address the possible role of COMT in 
feeding behaviour. Our studies revealed that acute COMT inhibition affects the feeding 
pattern of rodents; COMT-inhibited animals have significantly more ''long'' meals (lasting 
300 sec or more) than vehicle-treated animals. Notably, a relatively short starvation 
period of 16 h induced a slight, albeit not significant, decrease in prefrontal and striatal 
COMT activity in mice. This finding is interesting, especially as COMT activity is 
thought to be rather robust, and may suggest the increased importance of COMT during 
altered physiological status. 
 
In conclusion, although the specific roles of MB-COMT and S-COMT remain partly 
obscure, their absence from presynaptic dopaminergic and noradrenergic neuron 
terminals suggests a secondary (and perhaps more modulatory) role of COMT in 
neurotransmitter metabolism in the brain. Furthermore, the observed decrease in COMT 
activity after a relatively short starvation period suggests that COMT has an increased 
importance during certain physiological states. 
Finally, the observed regulatory function of oestrogens on COMT activity and protein 
expression in vivo may be of clinical importance as COMT inhibitors are used as adjuncts 
in the treatment of PD.  
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1. Introduction 
 
"Catecholamines'' is an umbrella term used to describe dopamine, noradrenaline and 
adrenaline. These molecules are referred to as catecholamines because they have a 
characteristic catechol structure. All catecholamines are derived from the amino acid 
tyrosine, which is converted into L-3,4-dihydroxyphenylalanine (L-dopa) by the enzyme 
tyrosine hydroxylase (Fig. 1). Dopamine is the first catecholamine synthesised from dopa. In 
turn, noradrenaline and adrenaline are derived from further metabolic modification of 
dopamine. All catecholamines are vital neurotransmitters and hormones that play important 
roles in the regulation of physiological processes. The degradation of catecholamines occurs 
either via O-methylation by catechol-O-methyltransferase (COMT) or by deamination by 
monoamine oxidase (MAO) (Fig. 1). Dysfunction of dopaminergic signalling may lead to 
diseases such as Parkinson’s disease and schizophrenia, whereas dysfunctions of the major 
noradrenergic pathways are mainly related to mood disorders. 
The O-methylation of catechols via COMT was first described more than five decades 
ago (Axelrod et al., 1958), but the true function, regulation, physiological and 
pharmacological importance of COMT has only gradually been revealed. COMT is an 
intracellular enzyme that exists in membrane-bound (MB-COMT) and soluble forms (S-
COMT) (Tenhunen et al., 1994). However, the necessity and physiological importance of the 
two COMT isoenzymes remains partly unknown. Both COMT isoforms are biologically 
active and share the same substrate spectrums. Their primary function is the metabolism of 
catecholamines (reviewed by Männistö & Kaakkola, 1999). All catecholamines have a 
common precursor molecule, L-dopa (Fig. 1), which is also metabolised via COMT. 
Despite their similarities, the expression profiles of the two COMT isoenzymes vary 
among tissues. Generally, S-COMT predominates in most tissues by a factor of 3 or higher 
except in the brain, where MB-COMT prevails (Tenhunen et al., 1994). However, the exact 
distribution profiles of MB-COMT and S-COMT remain obscure due to a lack of isoform-
specific antibodies. As previously mentioned, the primary function of COMT is the 
metabolism of catecholamines. The general view is that the oxidation of catecholamines via 
MAO is the predominant metabolic pathway and O-methylation via COMT plays only a 
subordinate role (Eisenhofer et al., 2004). This is because the majority of catecholamines 
released during synaptic transmission are quickly reuptaken into the presynaptic neuron via 
specific transport systems. Because COMT is not localised in presynaptic neurons, its 
contribution to catecholamine metabolism is rather minor in most parts of the brain. The 
lesser importance of COMT is furthermore supported by the fact that it is possible to lead a 
normal life in the absence of the COMT gene. COMT gene-deficient mice are healthy and 
fertile (Gogos et al., 1998), whereas MAO-deficient mice exhibit severe neurodevelopmental 
abnormalities (Cases et al., 1995; Upton et al., 1999; Bou-Flores et al., 2000; Yang et al., 
2001; Holschneider et al., 2002). 
Nevertheless, O-methylation via COMT constitutes the main metabolic pathway of 
dopamine in the prefrontal cortex (PFC). As the PFC, unlike other brain areas, contains very 
few dopamine transporters, COMT accounts for approximately 60% of dopamine metabolism 
(Tunbridge et al., 2004a; Yavich et al., 2007; Käenmäki et al., 2010). 
Catecholamines also play an important role in peripheral tissues. Noradrenaline, for 
instance, acts as a chemical transmitter at sympathetic postganglionic endings. The adrenal 
medulla synthesises and secretes catecholamines into the circulation as part of a diffuse 
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sympathetic discharge during activation of the sympathetic nervous system. In addition, 
kidney dopamine plays a major role in the regulation of natriuresis. Apart from its role in the 
metabolism of endogenous catecholamines, COMT also functions as an enzymatic barrier 
and protects tissues and organs from possibly harmful and biologically active exogenous 
catechol compounds. High COMT activities are therefore found in the blood-brain barrier 
(BBB), liver and gut wall (Männistö & Kaakkola, 1999). 
Furthermore, COMT is of paramount importance in the metabolism of catechol 
oestrogens, which are derived from oestrogen metabolism. The general assumption is that 
high COMT activity protects against oxidative DNA damage from catechol oestrogen 
metabolites, which have been proposed to promote oestrogen-dependent carcinogenesis 
(Cavalieri et al., 1997). Accordingly, increased carcinogenesis has been associated with low 
COMT activity (Lavigne et al., 1997; Thompson et al., 1998; Palmatier et al., 1999; Matsui et 
al., 2000; Yim et al., 2001; Comings et al., 2003; Inoue et al., 2005; Tanaka et al., 2006; 
Tanaka et al., 2007). However, COMT inhibitors used in the treatment of Parkinson’s disease 
(PD) have proven fairly safe, and to date, no increase in cancer incidence has been reported in 
PD patients using COMT inhibitors as adjuncts to L-dopa therapy (recently reviewed by 
Haasio, 2010 and Kaakkola, 2010). COMT not only metabolises catechol oestrogens but, in 
turn, COMT gene expression depends on the hormonal status, and oestrogen and 
progesterone have both been reported to downregulate the expression of the COMT gene in 
vitro (Briggs & Briggs, 1973; Xie et al., 1999; Jiang et al., 2003; Salama et al., 2007). 
The present study was designed to gain new insight into the specific distribution 
patterns of MB-COMT and S-COMT, to verify the proposed hormonal regulation of COMT 
and to investigate its possible physiological role in feeding behaviour. The following chapters 
review our current knowledge of the distribution and regulation of the COMT enzyme. 
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Figure 1: Dopamine synthesis and metabolism. 
 4
2. Review of the literature 
 
2.1 Catechol-O-methyltransferase (COMT) 
 
The COMT enzyme was first described by Julius Axelrod in 1958 (Axelrod & Tomchick, 
1958; Axelrod et al., 1958). COMT catalyses the O-methylation of catechols, thus rendering 
them biologically inactive. The physiological substrates of COMT include L-dopa, 
catecholamines (dopamine, noradrenaline and adrenaline), their hydroxylated metabolites, 
catechol oestrogens (derived from oestrogen metabolism) and dihydroxyindolic intermediates 
of melanin. Apart from its pivotal role in the metabolism of endogenous compounds, COMT 
is important in the metabolism of exogenous xenobiotics and substances such as triphenols, 
dobutamine, α-methyldopa, dihydroxyphenyl serine, isoprenaline, rimiterol, carbidopa, 
benserazide, dietary polyphenols and other compounds containing a catechol group (Axelrod 
& Tomchick, 1958; Guldberg & Marsden, 1975; Maruyama et al., 1996; Lautala et al., 1999; 
Männistö & Kaakkola, 1999; Zhu et al., 2000; Zhu et al., 2001; Sipilä & Taskinen, 2004). 
 
2.1.1 The COMT gene 
 
The single COMT gene encodes two different isoforms, S-COMT and MB-COMT 
(Tenhunen et al., 1994). In humans, the COMT gene is located on chromosome 22, band 
q11.2 and contains 6 exons (Grossman et al., 1992). Two distinct promoters, P1 and P2, 
located on exon 3 regulate COMT gene expression (Tenhunen et al., 1994). The P1 promoter 
is located between the MB-COMT- and S-COMT-starting ATG codons and controls 
expression of the shorter (1.3 kb in human; 1.6 kb in rat) transcript, which only produces S-
COMT (Fig. 2). The upstream P2 promoter, however, was suggested to function 
constitutively and controls the expression of the longer (1.5 kb in human; 1.9 kb in rat) 
transcript, which can code for both S-COMT and MB-COMT. MB-COMT contains 
additional amino acids (50 in human and 43 in rat) that are not present in the 221-amino-acid 
S-COMT and function as hydrophobic membrane anchors (Bertocci et al., 1991; Lundström 
et al., 1991). Accordingly, the molecular weight of MB-COMT (30.0 kDa in human; 29.6 
kDa in rat) is slightly higher than that of S-COMT (24.4 kDa in human; 24.8 kDa in rat). 
Most tissues contain both COMT isoforms, but S-COMT is more abundant in peripheral 
tissues, whereas MB-COMT prevails in the brain (Männistö & Kaakkola, 1999). However, 
COMT protein and mRNA levels do not always correlate precisely because the longer 
transcript can code for both MB-COMT and S-COMT due to the leaky scanning mechanism 
of translation initiation, while the shorter transcript produces exclusively S-COMT 
(Tenhunen et al., 1994). 
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Figure 2: Structure of the COMT gene. The black lines represent introns, and boxes represent exons. The 
locations of the MB-COMT and S-COMT promoters, translation start codons MB-ATG and S-ATG and the 
translation stop codon TGA are also noted. Filled and open boxes correspond to translated and untranslated 
regions, respectively. CpG sites are indicated by lollipop signs. Adapted from Sasaki et al. 2003. 
 
2.1.2 Reaction mechanism of COMT 
 
COMT catalyses the transfer of the methyl group of S-adenosyl-L-methionine (SAM or 
AdoMet) to one of the hydroxyl groups of the catechol substrate in the presence of Mg2+ 
(Männistö & Kaakkola, 1999). The extent to which the hydroxyl group in the meta (3-
hydroxy)- or para (4-hydroxy)-position is methylated depends highly on the side chain of the 
substrate. Because the catechol ring exhibits a 30-degree tilt towards the active site, 
substituents at the para-position are guided into a hydrophobic pocket. The pocket 
accommodates hydrophobic substituents while repelling hydrophilic ones. Thus, para-O-
methylation is favoured for hydrophobic substituents, and meta-O-methylation is more 
favourable for polar substituents (Lan & Bruice, 1998). 
The compounds involved in the reaction bind in a specific order. First, SAM binds to COMT, 
followed by Mg2+, and finally, the catechol substrate. The enzyme complex is degraded in the 
reverse order of its formation (Lotta et al., 1995). 
 
 
Figure 3: COMT-catalysed meta-methylation of a catechol compound. SAM donates the methyl group to the 
reaction. The reaction occurs in the presence of Mg2+. 
 
2.1.3 Biochemical properties of COMT 
 
The COMT isoforms share many biochemical and kinetic properties. The kinetic mechanism 
described above is the same for MB-COMT and S-COMT. Furthermore, both enzymes are 
similar with respect to Ca2+ inhibition, optimal pH and requirement for Mg2+ (Borchardt et 
al., 1974; Rivett et al., 1982; Jeffery & Roth, 1984; Jeffery & Roth, 1985). The most 
prominent difference between MB-COMT and S-COMT is their Km values (Guldberg & 
Marsden, 1975; Rivett & Roth, 1982; Rivett et al., 1982; Lotta et al., 1995). The Km value of 
an enzymatic reaction represents the substrate concentration at which the reaction rate is half 
its maximum speed. Thus, a low Km value indicates that the enzyme has a high affinity for 
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the substrate. MB-COMT is a low-capacity, high-affinity enzyme, and its Km value for most 
substrates is approximately 10 times lower than that of S-COMT (Lotta et al., 1995). 
Exceptions to this general rule are catechol oestrogens, for which MB-COMT and S-COMT 
have similar Km values (Reid et al., 1986). By contrast, S-COMT has a very high capacity. At 
low physiological concentrations of substrate, O-methylation via MB-COMT is likely to 
predominate. However, if substrate concentrations exceed the saturation point of MB-COMT, 
O-methylation via S-COMT will increase in importance and eventually prevail (reviewed by 
Roth, 1992). 
 
2.1.4 Major physiological substrates of COMT in the brain 
 
Dopamine 
In the late 1950s, Carlsson and co-workers detected large amounts of dopamine in the basal 
ganglia and subsequently implicated dopamine in the Parkinson-like symptoms induced by 
reserpine (Carlsson et al., 1957; Carlsson et al., 1958; Carlsson, 1959). It was only then that 
dopamine, which was initially thought to be of importance solely as a precursor to the 
synthesis of noradrenaline and adrenaline, was recognised as an independent 
neurotransmitter. In the brain, dopaminergic neurons form four major ascending pathways, 
namely the nigrostriatal, the mesolimbic, the mesocortical and the tuberoinfundibular 
pathways. Accordingly, dopamine affects a variety of brain functions such as motor control, 
emotion, cognition and endocrine regulation. In most brain areas, the majority of dopamine 
released during synaptic transmission is quickly reuptaken into the presynaptic neuron via 
dopamine transporters (uptake1). Subsequently, the majority of dopamine is stored in 
vesicles, and only a small fraction is broken down into dihydroxyphenylacetic acid (DOPAC) 
by MAO (Fig. 1; reviewed by Eisenhofer et al., 2004). Reuptake of released dopamine and 
subsequent deamination via MAO account for approximately 80% of total dopamine 
degradation (Rivett et al., 1982). Because COMT is localised in glial cells and postsynaptic 
neurons, its contribution to dopamine metabolism is somewhat minor (approximately 20% of 
overall dopamine metabolism) as the low-affinity uptake2 is needed to transport dopamine 
into these cells. Therefore, COMT mainly functions to degrade dopamine that has escaped 
reuptake into the presynaptic neuron and to further break down DOPAC (Boulton & 
Eisenhofer, 1998) into homovanillic acid (HVA) (Fig. 1). An exception to this rule is the 
PFC, in which dopamine transporters are rare and COMT is responsible for 50-60% of 
dopamine metabolism (Tunbridge et al., 2004a; Yavich et al., 2007). A study by Rivett and 
colleagues (1982) investigated the relative contributions of MB-COMT and S-COMT in the 
metabolism of dopamine and concluded that MB-COMT accounts for approximately 70% of 
the total O-methylating activity at dopamine concentrations <10 µM. Thus, at normal 
physiological concentrations of dopamine, MB-COMT is more important than S-COMT. 
However, the study analysed human brain homogenates and therefore did not take into 
account any selective localisation of the enzymes and catecholamines within different cell 
types or brain regions. Nevertheless, the results provide an estimate of the potential total 
enzyme capacities. As mentioned previously, MB-COMT has a higher affinity for catechol 
substrates than S-COMT and becomes saturated at high extracellular concentrations of 
catecholamines, causing O-methylation by the low-affinity S-COMT to become predominant. 
S-COMT contributes more to overall O-methylation than MB-COMT when the substrate 
concentration is approximately 20 µM (for review see Roth, 1992). 
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Noradrenaline 
Noradrenaline is synthesised from dopamine via dopamine β-hydroxylase. Noradrenaline is 
released from the adrenal medulla into the blood as a hormone and is also a neurotransmitter 
in the central nervous system (CNS) and sympathetic nervous system, where it is released 
from noradrenergic neurons. Noradrenergic cell bodies are located in the locus coeruleus and 
project to the thalamus, hypothalamus, limbic forebrain structures and cerebral cortex, where 
noradrenaline modulates a wide variety of functions. Noradrenaline is often referred to as a 
''fight or flight'' chemical as it is responsible for the body's reaction to stressful situations. 
Several studies suggest that COMT is present in peripheral noradrenergic neurons (Crout and 
Cooper 1962; Jarrott et al. 1971; Jarrott and Iversen 1971). However, the presence of COMT 
in presynaptic noradrenergic neurons in the brain is still uncertain. Similar to dopamine, most 
of the noradrenaline released into the synaptic cleft is quickly taken back into the presynaptic 
neuron via noradrenaline transporters (uptake1). Once in the neuron, most of the 
noradrenaline is packed into storage vesicles, and only a small amount is immediately 
metabolised by MAO (reviewed by Eisenhofer et al., 2004). However, some of the 
noradrenaline escapes this presynaptic uptake and is taken up by glial cells via uptake2. 
Modelling studies to assess the contribution of COMT to the inactivation of noradrenaline 
revealed that MB-COMT accounts for the majority of noradrenaline metabolism 
(approximately 50%) at noradrenaline concentrations less than 1 µM (Rivett et al., 1982). At 
higher concentrations of noradrenaline, at which point MB-COMT approaches saturation, 
deamination via MAO becomes the predominant pathway of noradrenaline metabolism. The 
overall contribution of S-COMT to noradrenaline metabolism was estimated to be rather 
small (approximately 5%) and only significant at concentrations of noradrenaline higher than 
300 µM. However, it should be noted that this model used human brain homogenates and, 
therefore, did not take into account any selective localisation of the enzymes and 
catecholamines within different cell types or brain regions. Therefore, the results provide an 
estimate of the potential total enzyme capacities but may not mirror the exact physiological 
events. Apart from noradrenaline itself, the hydroxylated metabolites of noradrenaline are 
also substrates of COMT. 
 
Catechol oestrogens 
Oestradiol is a sex hormone that exerts its function by binding to oestrogen receptors. In pre-
menopausal women, oestradiol is the predominant oestrogen, both in terms of absolute serum 
levels as well as in terms of oestrogenic activity. However, during menopause, oestrone is the 
predominant circulating oestrogen. Oestradiol is also present in males and is produced as an 
active metabolite of testosterone, and male serum oestradiol levels are roughly comparable to 
those of postmenopausal women. Epidemiological studies strongly link exposure to oestrogen 
with an increased risk of cancer (for review see Cavalieri & Rogan, 2006). The catechol 
oestrogens 2-hydroxyoestradiol (2-OHE) and 4-hydroxyoestradiol (4-OHE) are among the 
major metabolites of oestrogen (Fig. 4). Oxidation of these metabolites produces oestrogen-
quinones (E-Q), which can react with DNA to form depurinating adducts, ultimately leading 
to cancer-initiating mutations (Stack et al., 1996; Cavalieri et al., 1997). In hepatic tissues, 2-
OHE and 4-OHE are inactivated by glucuronidation and sulphonation. However, in extra-
hepatic tissues, COMT is the key player in the inactivation of 2-OHE and 4-OHE (Yager & 
Liehr, 1996; Cavalieri et al., 1997). Of the two compounds, 4-OHE is more carcinogenic due 
to the higher level of depurinating adducts formed from its quinone. 2-OHE is generally the 
major catechol oestrogen formed from oestrogen metabolism. However, increases in the level 
of CYP 1B1 and other 4-hydroxylases could render the minor catechol oestrogen metabolite, 
4-OHE, the major one. If the conjugation of catechol oestrogens via methylation becomes 
insufficient, the competitive catalytic oxidation of 2-OHE and 4-OHE to their respective 
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quinones can occur. These quinones, if not abolished by glutathione conjugation, can react 
with DNA to form depurinating adducts that are released from DNA to generate apurinic 
sites. Error-prone repair of this damage leads to mutations that initiate breast cancer. Other 
cancers are discussed later. 
 
 
 
Figure 4: Oestradiol metabolism in extra-hepatic tissues. Adapted from Cavalieri et al. 2006. 
 
Levodopa (L-dopa) 
Parkinson’s disease is the most common neurodegenerative disease after Alzheimer’s disease 
and is characterised by a progressive loss of dopaminergic cells in the substantia nigra (SN) 
of the brain. L-dopa was first introduced in the 1950s and remains the mainstay of PD 
therapy. Dopamine cannot be used as a drug itself because it does not cross the BBB. 
However, as it is dopamine’s natural amino acid precursor, L-dopa is taken up into the brain 
from the plasma across the BBB by a low-affinity amino acid transport system. Once in the 
brain, L-dopa is decarboxylated intraneuronally into dopamine. L-dopa has proven effective 
for all symptoms of PD; however, there are well-established problems related to L-dopa 
treatment, e.g., the wearing-off phenomenon related to decreased plasma L-dopa 
concentrations and the on-off phenomenon, the etiology of which remains unknown 
(Jankovic, 2005; Waters, 2005). Ideally, the L-dopa concentration should remain constant 
during therapy as high L-dopa concentrations can lead to adverse effects such as dyskinesias. 
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The peripheral decarboxylation of L-dopa into dopamine constitutes another problem with 
therapy as high peripheral levels of dopamine can cause nausea, vomiting, blood pressure 
changes and collapse. Furthermore, only 1% of the orally administered L-dopa dose actually 
reaches the target cells due to peripheral decarboxylation. These problems are largely 
overcome by using a peripherally acting inhibitor of dopa decarboxylase (DDC), such as 
carbidopa and benserazide. These diminish the metabolism of L-dopa in peripheral tissues, 
thus increasing the availability of L-dopa to the brain. Consequently, this allows the 
administered L-dopa dose to be reduced and thereby decreases the severity of the side effects 
caused by peripherally formed dopamine. Under normal circumstances, approximately 70% 
of L-dopa is metabolised to dopamine via DDC. However, during combined therapy with L-
dopa and a DDC inhibitor, O-methylation via COMT becomes the major pathway (Le Witt, 
1989; Männistö & Kaakkola, 1990). Therefore, COMT inhibitors are commonly added to PD 
therapy as they increase the bioavailability and half-life of L-dopa and aid in maintaining 
more stable L-dopa levels in patients. 
 
2.2 COMT distribution 
 
2.2.1 Peripheral COMT 
 
In mammals, COMT is distributed ubiquitously in the body and has been located in most 
tissues investigated. The highest concentrations are found in the liver, kidneys and 
gastrointestinal tract (Guldberg & Marsden, 1975; Nissinen et al., 1988; Schultz, 1991; 
Männistö & Kaakkola, 1999). Table 1 gives a general overview of COMT distribution and 
activities in peripheral tissues of the human, rat and mouse. 
 
Liver and gut wall 
Both the liver and gut wall exhibit high COMT activities (reviewed by Männistö & 
Kaakkola, 1999). This is because most of the detoxification of catechols via COMT occurs in 
these two tissues. COMT functions as an enzymatic barrier, protecting tissues and organs 
from biologically active and possibly harmful circulating catechol compounds by preventing 
their free translocation in the body. Therefore, COMT is most active in structures related to 
first-pass metabolism, such as the liver and gut wall. However, COMT is also present in the 
BBB (Kaplan et al., 1979; Kaplan et al., 1981) and functions to protect the brain from 
potentially harmful catechols. 
 
Kidney 
COMT modulates the rate of dopamine metabolism and consequently the dopaminergic tone 
of the kidneys. Kidney dopamine exerts natriuretic and diuretic effects by activating D1-like 
dopamine receptors in the nephron (Jose et al., 1992). Activation of D1-like receptors in turn 
results in an inhibition of the main sodium transport mechanisms (namely Na+/K+ ATPase 
and Na+/H+ exchanger), which are located in the proximal tubulus of the kidney (Aperia et al., 
1987; Felder et al., 1990; Seri et al., 1990; Odlind et al., 1999). A study by Odlind and 
colleagues (2002) revealed that mice with reduced or absent COMT activity were unable to 
increase renal dopaminergic activity and produce normal natriuresis in response to sodium 
loading. Furthermore, COMT is more important than MAO in regulating dopamine-mediated 
natriuresis in the rat kidney (Odlind et al., 2001).  
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Hamsters treated with oestradiol or oestrone readily develop renal cancers (Kirkman, 
1959). However, the male Syrian hamsters used in these studies are particularly susceptible to 
developing renal cancers (Li & Li, 1990), and the same is fortunately not true for other 
animal species or humans. Nevertheless, COMT is the key player in the inactivation of the 
catechol oestrogens 2- and 4-OHE. In particular, 4-OHE has been implicated in cancer 
initiation as it can be oxidised to oestrogen-3,4-quinones, which in turn react with DNA. 
Weisz and colleagues demonstrated that the COMT protein is upregulated in the kidneys of 
hamsters treated with oestradiol, suggesting a role for COMT in cancer prevention (Weisz et 
al., 1998). Furthermore, oestrogens induce nuclear S-COMT in hamster kidney cells, 
suggesting that a portion of the upregulated cytosolic S-COMT may be transported into the 
nucleus to protect the DNA from possible oxidative damage induced by 2-OHE and 4-OHE 
(Weisz et al., 1998). 
 
Uterus and prostate 
Epidemiological evidence suggests that polymorphisms that result in reduced COMT 
activities are associated with an increased risk of endometrial cancer (Zhao et al., 2007). In 
addition, it has been reported that hypermethylation of the P2 promoter of COMT selectively 
inactivates MB-COMT and may contribute to endometrial carcinogenesis (Sasaki et al., 
2003). Evidence suggests that COMT may protect endometrial tissue against the carcinogenic 
effects of oestrogen metabolites. For instance, Salama and colleagues (2008) report that 
knockdown of COMT in human endometrial cells increases the propensity of oestradiol and 
catechol oestrogens to induce reactive oxygen species and neoplastic transformations. In 
accord with findings in the uterus, prostate cancers may also arise from an imbalance in 
oestrogen homeostasis (Bosland, 2000). Studies of rats treated with the catechol oestrogen 4-
OHE or its quinone form, oestradiol-3,4-quinone, suggest that prostate cancers arise in 
regions of the prostate that have lower levels of COMT (Cavalieri et al., 2002). Nevertheless, 
the currently used COMT inhibitors have proven fairly safe and do not seem to increase 
cancer incidence (recently reviewed by Haasio, 2010 and Kaakkola, 2010). 
 
Table 1: Tissue distribution of COMT in mammals reported from 1958-2011. Adapted from Guldberg and 
Marsden, 1975. 
Tissue Species COMT value Reference 
Liver 
 
 
 
 
 
 
 
Rat 
 
 
 
Mouse 
 
 
Human 
 
Human (♂) 
Human (♀) 
5.0 µmol metanephrine/g/hr 
22.0 µmol normetanephrine/g/hr 
2.8 µmol normetanephrine/g/hr 
 
2.3 µmol metanephrine/g/hr 
1.5 µmol normetanephrine/g/hr 
 
233.0 µmol metanephrine/g/hr 
 
577 pmol DHBAc/min/mg protein
499 pmol DHBAc/min/mg protein
Axelrod & Tomchick, 1958 
Crout et al., 1961 
Stock & Westermann, 1963 
 
Axelrod & Tomchick, 1958 
Stock & Westermann, 1963 
 
Agathopoulos et al., 1971 
 
De Santi et al., 1998 
De Santi et al., 1998 
 
 
 11
Table 1 (continued): Tissue distribution of COMT in mammals reported from 1958-2011. Adapted from 
Guldberg and Marsden, 1975. 
 
Tissue Species COMT value Reference 
Adipose 
tissue 
 
 
Rat 
 
 
Mouse 
0.08 µmol normetanephrine/g/hr 
0.11 µmol normetanephrine/g/hr 
 
0.03 µmol normetanephrine/g/hr 
Stock & Westermann, 1963 
Horst et al., 1969 
 
Stock & Westermann, 1963 
Kidney 
 
 
Rat 
 
Human 
2.1 µmol metanephrine/g/hr 
 
159 pmol DHBAc/min/mg protein
Axelrod & Tomchick, 1958 
 
De Santi et al., 1998 
Spleen 
 
 
Rat 
 
Mouse 
0.5 µmol metanephrine/g/hr 
 
18.9 nmol DHBAc/mg protein/hr 
 Axelrod & Tomchick, 1958 
 
Axelrod et al., 1959 
Small 
intestine 
 
Jejunum 
 
 
Jejunum 
 
 
Ileum 
 
 
Ileum 
 
Rat 
 
 
Human 
 
 
Human 
 
 
Human 
 
 
Human 
0.3 µmol metanephrine/g/hr 
 
 
242 pmol DHBAc/min/mg 
protein (S-COMT) 
 
39 pmol DHBAc/min/mg protein 
(MB-COMT) 
 
70 pmol DHBAc/min/mg protein 
(S-COMT) 
 
60 pmol DHBAc/min/mg protein 
(MB-COMT) 
Axelrod. & Cohn, 1971 
 
 
Schultz, 1991 
 
 
Schultz, 1991 
 
 
Schultz, 1991 
 
 
Schultz, 1991 
 
2.2.2 COMT in the central nervous system (CNS) 
 
COMT is an intracellular enzyme (Ulmanen et al., 1997; Weisz et al., 1998; Männistö & 
Kaakkola, 1999), and therefore substrates must be transported into the cells prior to 
methylation (Guldberg & Marsden, 1975; Ulmanen et al., 1997; Männistö & Kaakkola, 
1999). Both MB-COMT and S-COMT are present in the brain but are located in different 
subcellular compartments. The additional anchor region of the MB-COMT enzyme attaches it 
to the rough endoplasmic reticulum, whereas S-COMT is present in the cytosol (Jeffrey and 
Roth 1984; Roth 1992). It has been proposed that MB-COMT resides in postsynaptic neurons 
and dendritic processes and is actively involved in the metabolism of catecholamines that 
have escaped neuronal uptake after synaptic transmission (Rivett et al., 1983; Kaakkola et al., 
1987; Tokunaga & Ishikawa, 1992). This hypothesis is further supported by the fact that O-
methylation via MB-COMT predominates at normal physiological concentrations of 
catecholamines in the brain (Rivett & Roth, 1982; Rivett et al., 1982; Roth, 1992). S-COMT, 
by contrast, has a much higher capacity (albeit lower affinity) for catecholamines and is 
primarily associated with glial cells. The physiological importance of S-COMT increases 
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during certain insults and treatments, suggesting that S-COMT protects neurons by 
decreasing oxidative stress. Supporting this hypothesis, glial S-COMT is upregulated 
following lipopolysaccharide (LPS) treatment (Helkamaa et al., 2007). Furthermore, the 
intrastriatal injection of fluorocitrate increases microglial COMT activity (Reenilä et al., 
1997). Similarly, oestradiol treatment induces nuclear S-COMT in the hamster kidney, 
possibly to protect DNA from oxidative damage induced by oestrogen metabolites (Weisz 
1998). Furthermore, due to its significantly higher Vmax value, S-COMT most likely 
predominates during oral L-dopa treatment in PD (Roth, 1992; Lotta et al., 1995; Bonifati & 
Meco, 1999).  
COMT activity, protein levels and mRNA levels are fairly similar throughout the 
different brain areas (Guldberg & Marsden, 1975; Roth, 1992; Tenhunen & Ulmanen, 1993; 
Tenhunen et al., 1994; Hong et al., 1998). However, the COMT activity in the choroid plexus 
is approximately 9-fold higher than that observed in the whole brain (Kaplan et al., 1981). 
Matsumoto and colleagues (2003) reported that COMT mRNA levels are highest in the PFC 
of humans and rats, underscoring the importance of COMT in the regulation of prefrontal 
dopamine levels. However, the protein and mRNA levels of COMT correlate poorly, possibly 
because not all mRNA is necessarily translated into protein synthesis and proteins may be 
transported to other regions by means of axonal transport. Additionally, the longer MB-
COMT transcript can result in both MB-COMT and S-COMT (Tenhunen et al., 1994). The 
relative amounts of MB-COMT and S-COMT vary widely between different tissues and 
species. For example, the amounts of MB-COMT and S-COMT are similar in the PFC of 
mice (Hill et al., 2007; Käenmäki et al., 2009), whereas marmosets display a clear dominance 
of S-COMT in the striatum (Zeng et al., 2010). 
 
2.3 Physiological role of COMT 
 
Some general considerations 
There are several general points to consider when evaluating the results of studies exploring 
the physiological importance of COMT. 
First, gender is an important factor in neuroscience (Cahill, 2006), and many parameters of 
brain function and structure vary between men and women (de Courten-Myers, 1999; De 
Bellis et al., 2001; De Vries, 2004). Sex differences are frequently observed in the correlation 
between various diseases/phenotypes and COMT polymorphisms. Sex-specific effects of 
COMT are usually attributed to transcriptional regulation by oestrogens (Xie et al., 1999; 
Jiang et al., 2003), and COMT is of particular importance in females because of its role in the 
detoxification of catechol oestrogens (Männistö & Kaakkola, 1999). As a consequence, 
COMT may influence brain function and dysfunction in a sexually dimorphic manner. 
Second, apart from sex differences, environmental factors may also contribute to the 
differences observed between men and women. For example, the lower global prevalence of 
alcohol abuse in females compared with males is believed to result from a combination of 
biological as well as social factors (Schulte et al., 2009). It is simply less acceptable for a 
woman to get ''totally wasted'' than it is for a man. 
Furthermore, the frequencies of COMT polymorphisms vary considerably among 
populations (Palmatier et al., 1999). As a consequence, significant correlations are more 
likely to be found in homogeneous populations. 
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Lastly, recent evidence suggests that different COMT haplotypes [formed by several 
single-nucleotide polymorphisms (SNPs)], rather than SNPs, may be more important in the 
analysis of genetic variations (Nackley et al., 2006). 
 
2.3.1 Genetic COMT polymorphisms 
 
The human COMT gene contains several SNPs. However, the best-studied is the Val158Met 
polymorphism as most other common COMT SNPs are non-coding. Therefore, the Val158Met 
polymorphism will be the main focus of this chapter. 
The human Val158Met polymorphism arises from a single nucleotide substitution of G 
→ A, which results in a valine to methionine substitution in exon 4 at codon 158 in MB-
COMT and at codon 108 in S-COMT (Bertocci et al., 1991; Lundström et al., 1991). The 
Met158 form of COMT is less thermostabile and therefore has a lower activity level at 37˚C 
than the Val158 form (Lotta et al., 1995; Chen et al., 2004). Individuals homozygous for 
Met158 have approximately 40% lower COMT activity in the PFC than Val158 homozygotes 
(Chen et al., 2004). 
Because of the particular importance of COMT in the regulation of prefrontal 
dopamine levels, the Val158Met polymorphism has been studied in a number of psychiatric 
diseases. The possible association of schizophrenia with COMT polymorphisms has been of 
particular interest because schizophrenia is associated with dysfunction of the dopamine 
system and the PFC (Grace, 1993; Goldman-Rakic et al., 2001; Weinberger et al., 2001). 
Several studies have identified the COMT locus as a susceptibility locus for schizophrenia 
(Coon et al., 1994; Badner & Gershon, 2002; Lewis et al., 2003). Furthermore, patients 
suffering from velo-cardiofacial syndrome, a disease associated with microdeletions of 
chromosome 22q11, demonstrate a greatly increased incidence of psychiatric disorders, 
particularly schizophrenia (Murphy et al., 1999). Complementing these findings, the 
incidence of 22q11 deletions is increased in schizophrenic patients compared with the normal 
population (Bassett & Chow, 1999). The literature concerning the association of the COMT 
gene with schizophrenia is rather large, and a full discussion of this topic is beyond the scope 
of this thesis. Nevertheless, meta-analyses indicate that the Val158 allele may be a weak risk 
factor for schizophrenia (Glatt et al., 2003). 
Genetic associations between COMT and various psychiatric phenotypes frequently 
(but not always) show differences between men and women. For instance, the low-activity 
Met158 allele is associated with obsessive-compulsive disorder in men but not in women 
(Karayiorgou et al., 1997; Karayiorgou et al., 1999; Poyurovsky et al., 2005). Anxiety-related 
phenotypes have been repeatedly, albeit often weakly, associated with the Met158 allele in 
women but not in men (Eley et al., 2003; Enoch et al., 2003; Olsson et al., 2005; Stein et al., 
2005), in agreement with findings for anxiety disorder (Domschke et al., 2004; Rothe et al., 
2006) and the increased anxiety found in female but not male COMT gene-deficient mice, as 
described later. Furthermore, the Val158 allele is associated with sensation-seeking behaviour 
in women but not in men (Lang et al., 2007). Finally, boys, rather than girls, carrying the 
Met158 allele perform better in a range of cognitive tests (Barnett et al., 2007). In line with the 
findings of Barnett and colleagues, individuals carrying the Met158 allele demonstrate 
improved working memory and executive function compared with Val158 allele carriers (Egan 
et al., 2001). 
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The role of COMT polymorphisms in the risk for addiction (such as nicotine-
dependence, alcoholism, opiate abuse, stimulant abuse, and cannabinoid use) has been 
recently reviewed by Tammimäki and Männistö (2010). Overall, the authors concluded that 
the correlation between addiction and COMT polymorphisms is small at best. A notable 
exception, however, is smoking; the Val158 allele represents a risk factor for smoking 
initiation and persistence. 
The impact of the Val158Met polymorphisms on acute pain remains unclear; some 
studies report an association and others claim that there is none (reviewed by Kambur & 
Männistö, 2010). However, a study in cancer patients revealed that carriers of the high-
activity Val158 allele required higher doses of morphine to combat cancer pain than carriers of 
the low-activity Met158 allele (Rakvåg et al., 2005; Reyes-Gibby et al., 2007). 
 
2.3.2 Studies with COMT-inhibitors 
 
In humans, the use of COMT inhibitors is currently limited to their role as adjuncts in the 
treatment of PD (see also chapter 2.1.5, Levodopa). COMT inhibitors are generally well-
tolerated, and their main adverse effects are related to dopaminergic and gastrointestinal 
events (Männistö & Kaakkola, 1999). Notably, it has been suggested that the inhibition of 
COMT could increase the production of free radicals in L-dopa-treated patients (Kuhn et al., 
1998). This theory is based upon the assumption that L-dopa and dopamine levels are 
elevated and their metabolism is then redirected to the oxidative route (Jenner & Olanow, 
1996; Fahn, 1997). However, in vivo studies with COMT-deficient mice do not support this 
hypothesis as the mice fail to exhibit increased oxidative stress under basal conditions as well 
as under amphetamine load (Forsberg et al., 2004). Furthermore, chronic high-dose L-dopa 
treatment does not increase oxidative damage in healthy cynomologus monkeys (Lyras et al., 
2002), and a post-mortem study of PD patients revealed that PD progression does not seem to 
be enhanced by chronic L-dopa use (Parkkinen et al., 2011). 
COMT inhibitors are widely used as a research tool to investigate the physiological 
role of COMT. Previous studies in rats using selective COMT inhibitors have shown that 
extracellular dopamine levels remain unaltered in the absence of any other pharmacological 
manipulation (Raevskii et al., 2002; Napolitano et al., 2003). However, under conditions of 
evoked dopamine release, e.g., after the administration of L-dopa, COMT inhibitors enhance 
the effect on dopamine levels (Huotari et al., 1999). For a more detailed discussion of this 
topic, please refer to the introduction in original publication IV. 
It is widely accepted that abnormal PFC biology results in deficient cognition and is a 
primary problem in schizophrenia. Dopamine levels in the PFC are critical for modulating 
cognitive function, and evidence supports the existence of an inverted U-shape relationship 
(Fig.5)  between dopamine activity in the PFC and working memory performance (Goldman-
Rakic et al., 2000). At baseline, COMT activity in Val158 homozygotes is associated with 
suboptimal (too little) PFC dopamine, whereas Met158 homozygotes have near-optimal PFC 
dopamine levels (for review see Tunbridge et al., 2006). A human trial found that 
administration of tolcapone, a centrally acting COMT inhibitor, dose-dependently improved 
working memory in Val158 allele carriers (Bitsios & Roussos, 2011). The activity of rat 
COMT resembles that of the human Val158 form (Lachman et al., 1996), and rats treated with 
tolcapone exhibit significantly improved extradimensional set shifting, a task dependent on 
PFC function (Tunbridge et al., 2004a). Furthermore, tolcapone may be effective in the 
treatment of depression (Moreau et al., 1994; Fava et al., 1999). 
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The effect of COMT inhibition on pain perception has been recently reviewed by 
Kambur and Männistö (2010). The effect of COMT inhibition is largely dependent on the 
nature of the pain. For instance, in acute and inflammatory pain models, COMT inhibitors 
seem to sensitise animals to nociceptive stimuli (Diatchenko et al., 2005; Kambur et al., 
2010; Nackley et al.,  2007), whereas in animal models of neuropathic pain, COMT inhibitors 
exhibit an anti-allodynic effect (Kambur et al., 2011; Pertovaara et al., 2001). 
In the kidney, inhibition of COMT causes significantly increased natriuresis (Eklöf et 
al., 1997; Odlind et al., 2001) by inhibiting the Na+/H+ exchanger and Na+/K+ ATPase in the 
proximal tubuli (Eklöf et al., 1997; Odlind et al., 1999; Vieira-Coelho et al., 2001). 
 
 
 
Figure 5: The inverted U-shape model of the association between dopamine signalling and PFC function. 
Circles: Val homozygous individuals, squares: Met homozygous individuals. The small arrows indicate the 
change in dopaminergic signalling and PFC function in response to treatments that increase dopamine 
concentrations (modified from Tammimäki & Männistö, 2010). 
 
 
2.3.3 Studies with genetically modified mice 
 
COMT gene-deficient mice 
COMT gene-deficient mice represent another valuable tool for the investigation of the 
physiological role of COMT. Although COMT-deficient mice lack both COMT isoforms 
from birth, they are healthy, fertile and exhibit normal motor function (Haasio et al., 2003). 
Under normal conditions, COMT deficiency does not affect brain dopamine levels despite 
considerably elevated DOPAC concentrations (Huotari et al., 2002). However, upon L-dopa 
administration, dopamine levels are elevated in the PFC and hypothalamus of COMT-
deficient mice (Huotari et al., 2002). 
Deficits in working memory have been described as a core cognitive feature of 
schizophrenia and are related to PFC dopamine function (Vijayraghavan et al., 2007). 
Papaleo and colleagues (2008) investigated the effect of COMT gene deletion on the working 
memory of mice and found that COMT deficiency resulted in improved working memory 
performance. 
A battery of behavioural tests, conducted in COMT gene-deficient mice, revealed a 
number of sex-dependent behavioural changes in these animals. For instance, male, but not 
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female, COMT-deficient mice exhibit higher levels of aggressiveness than their wild type 
littermates (Gogos et al., 1998). Furthermore, male COMT-deficient mice display a 
significantly higher preference for ethanol than their wild type littermates (Tammimäki et al., 
2008). Such an effect is not observed in female COMT-deficient mice. Conversely, female, 
but not male, COMT gene-deficient mice show greater anxiety and sensitivity to stress than 
wild type mice (Gogos et al., 1998; Papaleo et al., 2008). 
The effect of COMT deficiency on pain perception remains controversial. A study by 
Papaleo and colleagues (2008) found that COMT-deficient mice display increased pain 
sensitivity, whereas Kambur and co-workers (2008) could not detect any differences in 
baseline pain sensitivity between COMT-deficient and wild type mice. The manner in which 
pain sensitivity is measured seems to be of particular importance. For instance, in the hot 
plate test, the anti-nociceptive effect of morphine is enhanced in COMT-deficient mice, 
whereas in the tail flick test, the anti-nociceptive effect of morphine is reduced (Kambur et 
al., 2008). 
As aforementioned (see chapter 2.2.1, Kidney), COMT plays a significant role in the 
metabolism of renal dopamine. Dopamine promotes natriuresis by inhibiting the sodium 
transport proteins in the renal tubules. Renal sodium in turn plays a major role in the 
regulation of long-term blood pressure. When kept on a normal diet, the blood pressure 
values of wild type and COMT-deficient mice are similar (Helkamaa et al., 2003). However, 
a high-sodium diet evokes an increase in blood pressure, whereas COMT-deficient mice are 
resistant to such effects (Helkamaa et al., 2003). The authors proposed that the sodium-
resistance of COMT gene-deficient mice is due to an increased dopaminergic tone, which 
enables more efficient natriuresis at a lower blood pressure. 
 
COMT over-expressing mice 
To date, only two publications have investigated the effect of COMT over-expression in 
mice. Papaleo and colleagues (2008) utilised mice over-expressing the human COMT-Val 
variant (COMT-Val-tg mice). These mice are healthy and do not exhibit any physical 
disabilities (Papaleo et al., 2008). Complementing previous findings in COMT gene-deficient 
mice, COMT-Val-tg mice exhibit deficits in working memory but display blunted stress 
response and pain sensitivity (Papaleo et al., 2008). Suzuki and co-workers used mice over-
expressing the human 22q11 segment. These bacterial artificial chromosome (BAC) 
transgenic (TG) mice exhibit a 2-fold increase in COMT activity in the PFC, striatum and 
hippocampus (Suzuki et al., 2009). BAC TG mice, like COMT-Val-tg mice, exhibit some 
deficits in working memory but show enhanced incentive learning. 
 
2.4 COMT gene regulation 
 
2.4.1 Regulation of COMT by oestrogen and progesterone 
 
Oestrogen 
Reports of altered COMT activity during pregnancy (Briggs & Briggs, 1973; Parvez et al., 
1975; Parvez et al., 1976) and the menstrual cycle (Parvez et al., 1978), as well as the finding 
that COMT activity is lower in women than in men (Boudikova et al., 1990), were the first 
indicators of the sensitivity of COMT to hormones. Oestrogen seemed a particularly suitable 
candidate for COMT regulation, given that women have higher oestrogen levels than men. In 
1999, Xie and colleagues identified the mechanism underlying the oestrogenic regulation of 
COMT by demonstrating the presence of two oestrogen response elements in the COMT P2 
promoter. In cells containing oestrogen receptors, exposure to oestradiol resulted in reduced 
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COMT mRNA expression, whereas this effect was not observed in the absence of oestrogen 
receptors. In a follow-up paper, the same group later demonstrated that COMT protein 
expression and activity are also downregulated by oestrogen (Jiang et al., 2003). However, 
the effects of oestrogen on COMT seem to be more complex than a simple downregulation. 
Weisz and colleagues (1998) report that exposure to oestrogen increases COMT protein 
expression in hamster kidneys. A more recent study in oestrogen-deficient aromatase knock-
out mice (Hill et al., 2007) further supports the assertion that oestrogenic COMT regulation is 
tissue-specific as the group reports differential effects on COMT expression in different brain 
regions. The tissue-specific variations in oestrogenic COMT regulation may be partially due 
to differences in COMT's importance and role. For example, in mammary tissue and the 
prostate, COMT may protect against the genotoxicity and cytotoxicity generated by catechol 
oestrogens by preventing their conversion to quinones.  
 
Progesterone 
Response elements are short sequences of DNA located within the gene promoter region that 
can bind a specific transcription factor and regulate gene transcription. Progesterone regulates 
COMT expression via progesterone response elements (PREs) located in both COMT 
promoters (Salama et al., 2007; Salih et al., 2008). Site-directed mutagenesis of these PREs 
reverses the effect of progesterone on COMT. Progesterone can either up- or downregulate 
COMT expression, depending on the tissue-specific expression of progesterone receptors 
(PR). In the presence of PR-A, progesterone upregulates COMT expression, whereas in the 
presence of PR-B progesterone decreases COMT expression. If both receptors are present at 
similar levels, the net effect of progesterone is to increase COMT expression (Salih et al., 
2008). Although the precise molecular mechanism underlying the differential effect of PR-A 
vs. PR-B remains unclear, differences in cofactor recruitment and usage between the two PR 
isoforms may be involved (Giangrande et al., 2000; Salih et al., 2008). 
 
2.4.2 Regulation of COMT by environmental factors and drugs 
 
A number of environmental factors and drugs have been reported to alter COMT expression. 
Intrastriatal infusion of fluorocitrate, an astroglial toxin, increases COMT immunoreactivity 
and activity in microglial cells (Reenilä et al., 1997). Accordingly, local infusion of LPS, a 
potent activator of microglial cells, gradually increases microglial COMT activity and protein 
expression over a 14-day period (Helkamaa et al., 2007). Interestingly, S-COMT levels 
exhibit a stronger increase in response to LPS. This is of particular interest because S-COMT 
has a higher capacity (albeit lower affinity) than MB-COMT and may serve as a ''line of 
defence'' during pathological situations. Although this hypothesis remains to be confirmed, 
several studies support it. For instance, microglial COMT is upregulated in a rat model of 
traumatic brain injury (Redell & Dash, 2007). Furthermore, local infusion of kainic acid to 
the striatum causes a selective destruction of neuronal cells followed by a marked increase of 
COMT in glial cells (Rivett et al., 1983; Kaakkola et al., 1987; Naudon et al., 1992). 
In addition to environmental insults, certain drugs are also able to alter COMT 
expression. Administration of L-dopa to mice causes a significant increase in COMT 
expression and activity (Zhao et al., 2007). Furthermore, entacapone, a peripherally acting 
COMT inhibitor, increases S-COMT activity in red blood cells of PD patients (Maltete et al., 
2011). By contrast, psychotropic agents such as clozapine, haloperidol, lithium and sodium 
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valproate cause a significant downregulation of S-COMT mRNA, whereas MB-COMT 
mRNA levels were solely downregulated by sodium valproate (Fatemi & Folsom, 2007; 
Fatemi et al., 2009). 
Finally, there is also evidence that nutritional factors modify COMT expression. 
Folate deficiency can decrease COMT expression to undetectable levels (Duthie et al., 2008). 
Likewise, the soy isoflavones genistein and daidzein reduce COMT mRNA and activity 
levels via an ER-mediated pathway (Lehmann et al., 2008). Furthermore, COMT activity and 
protein expression are upregulated in Neotoma stephensi (Stephen’s woodrat), a dietary 
specialist with a diet consisting of 70% juniper, compared with animals that consume a more 
general diet (Skopec & Dearing, 2011). These findings further underline the importance of 
COMT in the detoxification of exogenous compounds. 
 
2.4.3 Regulation of COMT by tumour necrosis factor alpha 
 
Tumour necrosis factor alpha (TNFα) has been implicated in the regulation of COMT. 
Salama and colleagues (2009) were the first to report a significant decrease in COMT mRNA 
expression after TNFα treatment in endometrial glandular epithelial cells. These findings 
were subsequently extended to astrocytes (Tchivileva et al., 2009). Furthermore, the latter 
study revealed that the observed downregulation of COMT is due to binding of nuclear factor 
кB (NFкB) to a specific NFкB binding site in the promoter region of the COMT P2 promoter 
(Tchivileva et al., 2009). 
 
2.4.4 Regulation of COMT by epigenetic mechanisms 
 
The term epigenetic refers to the study of changes in gene expression that do not involve 
changes in the genetic code. Two molecular switches – methylation and acetylation – have 
received particular scrutiny (Bestor, 1998). Methylation usually results in the inactivation of 
the substrate, and methylation of the promoter area in DNA similarly decreases the 
transcription of the targeted gene. Hypomethylation and acetylation in turn activate genes. 
Accordingly, COMT mRNA expression can be modified by the methylation of cytosine 
residues in the regulatory CpG islands of the COMT promoter region. In endometrial cancer 
cell lines, the P2 promoter (controlling the expression of MB-COMT) is hypermethylated, 
leading to an inactivation of MB-COMT expression (Sasaki et al., 2003). Accordingly, 
hypomethylation of the P2 promoter leads to an overexpression of MB-COMT (Abdolmaleky 
et al., 2006) and has been associated with schizophrenia. However, post-mortem analysis of 
patients suffering from schizophrenia failed to observe any differences in COMT mRNA 
expression (Matsumoto et al., 2003; Tunbridge et al., 2004b). 
Recently, the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) has been 
implicated in the regulation of COMT. Fu and colleagues (2010) demonstrated that COMT 
mRNA levels are downregulated in response to TSA treatment in several breast cancer cell 
lines. These findings were confirmed by Bence and colleagues (2011), who report that TSA 
dramatically reduced COMT transcript levels in a neuroblastoma cell line. 
 19
3. Aims of the study 
 
Despite a 50-year history of intensive research, the true function, regulation, physiological 
and pharmacological importance of COMT has only gradually been revealed. Particularly the 
role and distribution of the two isoforms of COMT, namely S-COMT and MB-COMT, has 
remained obscure. However, the development of COMT inhibitors as adjuncts to L-dopa 
therapy in Parkinson’s disease, the understanding of COMT’s importance in the PFC and the 
observation that COMT activity is polymorphic and correlates with a number of diseases 
have all sparked new interest in COMT research. We have now studied the distribution, 
regulation and functions of COMT in rodents to gain more knowledge about its physiological 
role. 
 
The specific aims of this study were to: 
 
1. Elucidate the cellular localisation of COMT in the rat brain utilising dopaminergic and 
noradrenergic lesions. 
 
2. Investigate the distinct tissue and cellular localisations of MB-COMT and S-COMT in an 
S-COMT deficient mouse line. 
 
3. Verify the proposed hormonal regulation of COMT in rats via the manipulation of 
oestrogenic activity. 
 
4. Investigate the possible impact of low COMT activity/COMT gene knockout on the 
feeding behaviour of female rodents. 
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4. Materials and Methods 
 
For a more detailed description of the materials and methods used in this study, please refer 
to the respective original publications I-IV. 
 
4.1 Animals 
 
Female and male Wistar rats were purchased from Harlan Laboratories, Netherlands. The rats 
weighed 190-200 g at the beginning of the experiments. For study IV, we additionally used 
female C57BL/6 homozygous Comt-deficient (COMT -/-) mice and their wild-type 
littermates. COMT -/- mice were originally developed by Gogos et al. (1998) in a mixed 
129Sv x C57BL/6 background and were later backcrossed for more than 20 generations 
against a pure C57BL/6 background. Study II utilised S-COMT-deficient mice that were 
generated in house (for details see study II and its supplementary material). Mice were bred 
locally at the Helsinki University Laboratory Animal Centre, Helsinki, Finland, using 
heterozygous mice as breeding couples. To maintain the viability of the strain, it was 
enriched regularly by mating C57BL/6J females obtained from Harlan, Netherlands, with 
heterozygous males. The heterozygous offspring of these couples were then used for further 
breeding. All animals were either housed singly (study IV) or in groups of 2-4 (studies I and 
III) in clear polycarbonate cages. Animals were kept under a 12:12 h light/dark cycle with 
lights on from 06:00 to 18:00 and an ambient temperature of 20-22°C. Standard chow and tap 
water were available ad libitum, except when noted differently. All animal procedures were 
reviewed and approved by the National Animal Experiment Board and carried out in 
accordance with the European Communities Council Directive 86/609/EEC.  
 
4.2 Drugs and treatments 
 
OR-1139 (Ro 41-0960, 2'-fluoro-3,4-dihydroxy-5-nitrobenzophenone; see Fig. 6) was 
synthesised by Dr. Aino Pippuri (for a detailed description of the synthesis of OR-1139 
please refer to Borgulya et al., 1989) and injected intraperitoneally (i.p.) as a suspension in 
0.5% carboxymethylcellulose. OR-1139 is a centrally acting nitrocatechol COMT inhibitor 
with an oral ED50 of 0.28 mg/kg and an IC50 value of 42 nM (Borgulya et al., 1989; 
Learmonth et al., 2010). OR-1139 dose-dependently inhibits the formation of homovanillic 
acid and the metabolism of L-dopa to 3-O-methyldopa (Borgulya et al., 1989; Learmonth et 
al., 2010). N-(2-chloroethyl)-N-bromobenzylamine hydrochloride (DSP-4; Sigma, St. Louis, 
MO, USA) was dissolved in 0.9% saline and injected intraperitoneally. β-oestradiol (Sigma), 
tamoxifen citrate (Sigma), and testosterone propionate (Sigma) were dissolved in a minimal 
amount of 96% ethanol and diluted to a final working concentration with sesame oil (Sigma-
Aldrich, St. Louis, MO, USA). Desipramine hydrochloride (Sigma) was dissolved in sterile 
water. 6-Hydroxydopamine hydrochloride (6-OHDA HCl, Sigma) was dissolved in saline 
containing 0.02% ascorbic acid. Tramadol hydrochloride (Orion Pharma, Espoo, Finland) 
was administered subcutaneously (s.c.) to alleviate post-operative pain. Sodium pentobarbital 
(Orion Pharma) was used as an anaesthetic in perfusions. The drug doses were calculated as 
the free base and injected in a volume of 1 ml/kg. 
Female and male Wistar rats received 14-day hormonal treatments with either tamoxifen (500 
µg/kg) or oestradiol (100 µg/kg), respectively. Drugs were injected s.c. once a day for 14 
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days, after which the animals were sacrificed and tissues were collected for neurochemical 
analysis. 
Ovariectomised rats received 14-day treatments with oestradiol (100 µg/kg). Rats were 
ovariectomised by the supplier (Harlan, The Netherlands). 
 
 
 
Figure 6: Chemical structure of the centrally acting COMT inhibitor, OR-1139 (Ro 41-0960, 2'-fluoro-3,4-
dihydroxy-5-nitrobenzophenone). 
 
 
4.3 Immunohistochemistry (Study II) 
 
4.3.1 Tissue preparation 
 
The animals were anesthetised with sodium pentobarbital (100 mg/kg; i.p.) and subsequently 
perfused intracardially with phosphate-buffered saline, followed by 4% paraformaldehyde in 
0.1 M sodium phosphate buffer, pH 7.4. The brains and peripheral tissues were removed, 
postfixed for 4 h and later transferred to phosphate buffer containing 20% sucrose for storage 
at 4°C. 
 
4.3.2 Immunolabelling  
 
COMT immunohistochemistry 
 
Light microscopic COMT immunohistochemistry 
Paraffin-embedded sections from selected brain areas and peripheral tissues were used. 
Animals from each genotype were included in every run. In brief, sections were 
deparaffinised and processed in a microwave oven for antigen retrieval. Endogenous 
peroxidase activity was eliminated by incubation with 5% hydrogen peroxide and non-
specific binding was blocked with a Vector® M.O.M.TM Immunodetection Kit. Sections were 
then incubated for 60 min with mouse anti-COMT primary antibody (1:300, BD Biosciences 
Pharmingen, San Diego, CA, USA) and subsequently processed with a biotinylated horse 
anti-mouse secondary antibody (1:300 in M.O.M. diluent, Vector Laboratories, Burlingame, 
CA, USA) for 30 min. Stainings were visualised with diaminobenzidine and hydrogen 
peroxide. Sections of peripheral tissues were further counter-stained with Mayer’s 
haematoxylin to visualise the cell nuclei. Sections from all tissues (brain and periphery) were 
mounted on gelatine/chrome alum-coated slides, dehydrated with graded ethanols and cover-
slipped with Pertex® mounting medium. 
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Immunofluorescent microscopy 
Paraffin-embedded sections were processed as described above for light microscopic 
immunohistochemistry, with the exception that non-specific binding was blocked with 10% 
normal goat serum. Sections were incubated with the respective primary antibodies (rabbit 
anti-glial fibrillary acidic protein (GFAP), 1:500 (Chemicon, Billerica, MA, USA), for the 
identification of astrocytes; rabbit anti-ionised calcium-binding adaptor molecule 1 (Iba1), 
1:500 (Biocare Medical, Concord, CA, USA), for the identification of microglia; rabbit anti-
Na+/K+ ATPase, 1:500 (AbCam, Cambridge, UK) as a cell membrane marker)  overnight at 
4°C. The next day, the sections were incubated with a fluorescein-conjugated goat anti-rabbit 
secondary antibody (1:500, Pierce, Rockford, IL, USA) for 60 min.  
 
4.4 Immunoblotting (Studies I-III) 
 
Tissue samples were diluted 1:20 in homogenisation buffer (10 mM phosphate buffer, pH 
7.4, containing 0.5 mM dithiothreitol and 1 mM EDTA) and subsequently homogenised. The 
homogenates were then centrifuged at 900 g at 4°C for 10 min, and the supernatants were 
collected for further analysis. Protein concentrations were determined using a commercial 
BCA protein assay kit (Pierce). The samples were diluted with Laemmli buffer, and equal 
amounts of total protein (20µg) were loaded. Electrophoresis was performed in a 12% SDS-
polyacrylamide gel, and the samples were subsequently blotted onto a nitrocellulose 
membrane (Protran®, Schleicher & Schuell GmbH, Daseel, Germany). Non-specific binding 
was blocked with 5% nonfat dry milk, and the membranes were then incubated with mouse 
anti-COMT primary antibody (1:5000, BD Biosciences Pharmingen) and mouse anti-beta 
actin primary antibody (1:2000, Sigma) overnight with gentle shaking. The next day, the 
membranes were rinsed and processed with a secondary antibody conjugated with 
horseradish peroxidase. The blots were visualised with a chemiluminescent substrate (Pierce) 
and detected and estimated with a GeneGenome chemiluminescent detector and its software 
(SynGene, Synoptics LTD, UK). 
 
4.5 COMT activity analysis (Studies I-IV) 
 
The enzyme preparations were incubated with phosphate buffer (pH 7.4) containing 5 mM 
MgCl2, 200 mM SAM and 500 mM DHBAc. The reaction products, vanillic and isovanillic 
acid, were analysed by high-performance liquid chromatography  equipped with 
electrochemical detection.  
Total protein concentrations were determined with a commercial BCA protein assay kit 
(Pierce). COMT activity is expressed as picomoles of vanillic acid formed in one min per mg 
of total protein in the sample. 
 
4.6 Behavioural testing procedures (Study IV) 
 
Rats were habituated to the testing procedure by i.p. injection of 0.1 ml sterile saline and 16-h 
(overnight) fasting every third day for at least one week before the actual testing sessions. On 
the morning of the experiments, fasted rats were weighed and carried to the experiment room 
in their home cages 30 min prior to the first test. Rats were then injected with either vehicle 
or one of the 3 drug doses (OR-1139; 3, 10 or 30 mg/kg), and returned to their home cage. 
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Eight previously weighed food pellets were then placed on the grid of the animal’s cage. The 
pellets were weighed at 1, 2, 4, 8 and 24 h post-injection. Additionally, the rats were filmed 
with a web camera, positioned above the cage, during the first 4 h of re-feeding. The videos 
were subsequently analysed for individual feeding parameters. One week was allowed 
between testing sessions, and the experiment was repeated 3 times with each rat. 
The habituation procedure and experimental procedures for wild type mice were the same as 
described above for rats, with the exception that mice received only 3 previously weighed 
food pellets. 
COMT -/- mice did not receive i.p. injections of any type but were otherwise handled as 
described above for wild type mice. 
 
4.7 Lesions (Study I) 
 
4.7.1 6-OHDA lesions 
 
The stereotaxic operations were conducted under general isoflurane (4.5% during induction 
and 2-3% during maintenance) and local lidocaine anaesthesia. Rats received s.c. injections 
of tramadol (1 mg/kg) to alleviate post-operational pain. 
Injections of freshly prepared 6-OHDA were infused unilaterally at A/P = -5.3, L/M = -3.0, 
and D/V = -6.6 for lesions of the SN and at A/P = -5.3, L/M = -0.9, and D/V = -7.8 for 
lesions of the ventral tegmental area (VTA). Following surgery, animals were allowed to 
recover in individual cages for 1-2 days before being returned to their home cages. Rats were 
sacrificed 3 weeks after surgery, and tissue samples were collected for histological and 
neurochemical analyses. 
 
4.7.2 DSP-4 lesions 
 
DSP-4 is a commonly used neurotoxin. After i.p. administration, DSP-4 selectively destroys 
noradrenergic nerve terminals originating from the locus coeruleus while leaving other 
noradrenergic projections largely intact. Rats received i.p. injections of DSP-4 (50 mg/kg). 
The dose of DSP-4 was weighed separately for each animal, dissolved in saline and injected 
immediately. Control animals received saline injections. Two weeks post-treatment, rats were 
sacrificed, and tissue samples were taken for histological and neurochemical analyses. 
 
4.8 Statistics 
 
All values are expressed as the means ± SEM, and the criterion for statistical significance was 
p<0.05. Data obtained were analysed using one-way ANOVA followed by Tukey’s post hoc 
test (Studies III & IV) or by unpaired t-test when comparing two groups (Studies I, III & IV) 
with GraphPad Prism 5.0 program (GraphPad Software, Inc., San Diego, CA, USA). 
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5. Results 
 
5.1 COMT protein expression and activity after dopaminergic and 
noradrenergic lesioning of the rat brain (Study I) 
 
To investigate the presence of COMT in presynaptic dopaminergic or noradrenergic neurons, 
dopaminergic and noradrenergic toxins were applied to selected neuron populations. 
Lesioning of dopaminergic and noradrenergic neurons was assessed by measuring the 
dopamine and noradrenaline content in the projection areas of these neurons. Additionally, 
COMT protein expression and activity were examined in several projection areas to 
determine whether there were any changes in COMT values. Despite successful lesioning of 
the presynaptic dopaminergic and noradrenergic neurons, no changes in COMT protein 
expression or activity levels could be noted, strongly indicating that COMT is not present in 
presynaptic dopaminergic and noradrenergic neurons. 
 
5.1.1 Dopamine levels in the projection areas of the lateral SN after 6-OHDA 
lesioning 
 
Dopamine levels were decreased in the dorsal striatum (56.1% compared to the intact side) 
after selective lesioning of the lateral SN (Fig. 7A). In comparison, dopamine levels in other 
brain areas, e.g., the PFC and hippocampus, were not affected (Fig. 7A). Decreased dopamine 
levels in the dorsal striatum, the main projection area of the lateral SN, indicate a moderate 
but selective lesioning of presynaptic nigrostriatal dopaminergic neurons. 
 
5.1.2 Dopamine levels in the projection areas of the VTA after 6-OHDA 
lesioning 
 
Lesioning of the VTA with 6-OHDA resulted in decreased dopamine levels in the projection 
areas (Fig. 7B), namely the PFC (38.2% compared to the intact side), the dorsal striatum 
(8.3% compared to the intact side), and the nucleus accumbens (14.5% compared to the intact 
side). Other brain sites such as the hippocampus (93.1% compared to the intact side) 
remained unaffected (Fig. 7B). 
 
5.1.3 Effect of 6-OHDA lesions of the SN and VTA on COMT activity and protein 
expression 
 
No changes in COMT activity (Fig. 8A) or protein expression (Fig. 8B) were detectable in 
any of the projection areas 2 weeks after infusion of 6-OHDA to the lateral SN. Similarly, 6-
OHDA lesions of the VTA did not yield any differences in COMT activity or protein 
expression (Fig. 8A and 8B) in any of the analysed projection areas, indicating that COMT is 
not present in presynaptic dopaminergic neurons.  
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Figure 7: Dopamine levels in selected brain areas after 6-OHDA infusion to the lateral SN (A) or VTA (B). (C) 
Illustration of the two different pathways originating from the lateral SN and the VTA; n=5/group. 
 
 
 
 
 
Figure 8: COMT activity and protein expression levels after selective 6-OHDA lesions. Infusion of 6-OHDA to 
the lateral SN did not affect COMT activity (A) or protein expression (B) in any of the analysed projections. 
Similarly, lesioning of the VTA with 6-OHDA did not alter COMT activity (A) or protein expression (B); 
n=5/group. 
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5.1.4 Effect of DSP-4 lesions on noradrenaline levels in the projection areas of 
the locus coeruleus 
 
DSP-4 selectively destroys noradrenergic neurons originating from the locus coeruleus (see 
Fig. 9B). Significantly reduced tissue concentrations of noradrenaline in the projection areas 
of the locus coeruleus confirmed successful lesioning (Fig. 9A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: (A) Noradrenaline (NA) levels in selected brain areas after i.p. injection of DSP-4. (B) Illustration of 
the different projection pathways originating from the locus coeruleus; n=5/group. 
 
 
5.1.5 Effect of DSP-4 lesions on COMT activity and protein expression in the 
projection areas of the locus coeruleus 
 
Despite successful destruction of noradrenergic terminals, no changes in COMT activity (Fig. 
10A) or protein expression (Fig. 10B) could be noted. These observations suggest that 
COMT is not present in presynaptic noradrenergic terminals originating from the locus 
coeruleus. 
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Figure 10: COMT activity and protein expression levels after selective DSP-4 lesioning. Treatment with DSP-4 
failed to alter COMT activity (A) or COMT protein expression (B) in any area analysed, indicating that COMT 
is not located in noradrenergic terminals originating from the locus coeruleus; n=5/group. 
 
 
Table 2 summarises our main findings. Despite successfully lesioning presynaptic 
dopaminergic and noradrenergic neurons, COMT protein expression and activity in the 
projection areas remained unchanged. These results indicate that COMT is not present in 
presynaptic dopaminergic and noradrenergic neurons. 
 
 
Table 2: Summary of changes in catecholamine levels and COMT protein and activity levels after selective 
lesioning. Changes are expressed relative to the unlesioned, intact side (SN and VTA lesion) or relative to 
control animals (DSP-4 lesion). ↔ = unchanged; ↓ = slightly decreased; ↓↓ = moderately decreased; ↓↓↓ = 
strongly decreased. 
 
Lateral SN lesion Dopamine levels COMT protein COMT activity 
PFC ↔ ↔ ↔ 
Dorsal striatum ↓↓ ↔ ↔ 
Nucleus accumbens ↓ ↔ ↔ 
Hippocampus ↔ ↔ ↔ 
    
VTA lesion    
PFC ↓↓ ↔ ↔ 
Dorsal striatum ↓↓↓ ↔ ↔ 
Nucleus accumbens ↓↓↓ ↔ ↔ 
Hippocampus ↔ ↔ ↔ 
    
DSP-4 lesion Noradrenaline levels COMT protein COMT activity 
PFC ↓↓↓ ↔ ↔ 
Striatum ↓↓↓ ↔ ↔ 
Hypothalamus ↓↓ ↔ ↔ 
Hippocampus ↓↓↓ ↔ ↔ 
Cerebellum ↓↓↓ ↔ ↔ 
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5.2 COMT distribution in wild type and S-COMT-deficient mice 
(Study II) 
 
5.2.1 Whole-body distribution of the COMT protein 
 
To obtain an overall view of COMT distribution in the mouse, whole body sections of wild 
type mice were probed with a COMT antibody. The most intense stainings were obtained 
from the liver and kidneys, followed by the intestinal tract (Table 3). In comparison, the heart 
and brain were only faintly stained. Based on semiquantitative density measurements, the 
ratio between COMT protein in the liver and COMT protein in the brain was approximately 
5:1 (for more details, please refer to original publication II). 
In agreement with our immunohistochemical findings, the liver contained the highest levels 
of COMT protein, followed by the kidney, spleen and heart. By contrast, the brain, bladder 
and lungs contained relatively low levels of the COMT protein (Fig. 13). 
For a more detailed description of the cellular distribution of the COMT protein, please refer 
to Table 3. 
Altogether, COMT protein levels were much lower in the brain than in the periphery. The 
highest amounts of the COMT protein were found in the PFC and striatum, whereas the 
hippocampus and hypothalamus contained only small amounts of the COMT protein. The 
general distribution pattern of the COMT protein was similar in wild type and S-COMT-
deficient mice (as measured by western blot analysis; see also Fig. 13). 
 
Table 3: Peripheral distribution and cellular localisation of immunoreactive COMT in the wild type mouse. 
Staining intensities are based on visual observations. Key: - = no COMT-immunoreactivity (COMT-ir); ± = 
minor COMT-ir; + = low COMT-ir; ++ = moderate COMT-ir; +++ = high COMT-ir; n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organ 
 
Cell type 
 
Intensity of COMT-ir 
 
 
Lungs 
 
 
Alveoles 
Smooth muscle cells 
(bronchioles) 
 
± 
+ 
 
Heart 
 
 
Striations of intercalated disks 
Endothelial cells 
 
± 
+ 
 
Liver 
 
 
Hepatocytes 
Kupffer cells 
 
 
+++ 
- 
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Table 3 (continued): Peripheral distribution and cellular localisation of immunoreactive COMT in the wild 
type mouse. Staining intensities are based on visual observations. Key: - = no COMT-immunoreactivity 
(COMT-ir); ± = minor COMT-ir; + = low COMT-ir; ++ = moderate COMT-ir; +++ = high COMT-ir; n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.2 Distribution and cellular localisation of both COMT protein isoforms in 
the mouse brain 
 
The details of COMT distribution in the brains of wild type and S-COMT-deficient mice are 
illustrated in Figure 11. In general, COMT was relatively evenly distributed throughout the 
entire brain, and the distribution patterns were similar in wild type and S-COMT-deficient 
mice. Cerebral cortex layers 2-6 exhibited intense COMT-ir in large- and medium-sized 
pyramidal cells, interneurons and microglia. However, the staining intensities varied between 
distinct areas of the cerebral cortex. For example, the visual and motor cortices exhibited only 
moderate COMT-ir in comparison to the intense stainings observed in the primary 
somatosensory and auditory cortices. Although COMT protein analysis revealed a high 
amount of COMT protein in the PFC, only moderate COMT-ir was observed in this area. 
Striatal small and medium sized spiny neurons displayed abundant COMT-ir, with highest 
staining densities found in the dorsal and ventral striatum, and lateral globus pallidus. 
Surprisingly, the nucleus accumbens (core and shell regions) appeared to be only weakly 
stained. The pyramidal neurons of the hippocampal cornu ammonis (CA) exhibited 
substantial COMT-ir in fields CA1 and CA3. Likewise, areas with close connections to the 
hippocampus, such as the lateral septal area and septum, demonstrated high COMT-ir. In 
contrast, CA2 and the dentate gyrus displayed only moderate COMT-ir. The same was true of 
the amygdala, corpus callosum and anterior fissure. The SN revealed intensive COMT-ir in 
both the pars compacta and pars reticulata. Equally intense stainings were observed in the 
VTA and periaqueductal grey. The thalamus and hypothalamus displayed moderate COMT-
ir. The cerebellum exhibited high COMT-ir in the granular cell layer, whereas only minor 
COMT-ir could be detected in the molecular cell layer. 
 
Organ 
 
Cell type 
 
Intensity of COMT-ir 
 
Kidney (cortex) 
 
 
Squamous cell 
Tubular epithelial cells 
 
 
++ 
++ 
 
Spleen 
 
White pulp 
Red pulp 
 
+++ 
- 
 
 
 
Duodenum 
 
 
Epithelium cells 
Enterocytes 
Macrophages 
Goblet cells 
 
+++ 
+++ 
+++ 
- 
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Notably, based on respective marker proteins, COMT-ir was consistently detected in 
microglial cells throughout the entire brain. In contrast, astroglial cells contained only very 
little COMT. 
 
 
Figure 11: Distribution of immunoreactive COMT in the brains of wild type (Wt) and S-COMT-deficient  
(S-COMT -/-) mice; n=3/group. 
 
5.2.3 Distribution of COMT activity 
 
COMT activities largely correlated with COMT protein expression. For instance, the liver 
and kidneys exhibited high COMT activities, whereas COMT activity in the lungs was rather 
low (Fig. 12). This applied for both wild type and S-COMT-deficient mice.  
In the brain, COMT activities were highest in the PFC and striatum and lowest in the 
hippocampus (Fig. 12). Again, this finding was true for both wild type and S-COMT-
deficient mice. With the exception of the hippocampus, in which COMT activities were 
similar in both genotypes, COMT activities were significantly lower in S-COMT-deficient 
mice than in wild type mice in all of the analysed tissues (Fig. 12).  
 
 
 
 
 
 
 
 
 
 
Figure 12: Distribution of COMT 
activities in wild type (Wt) and S-
COMT-deficient (S-COMT -/-) 
mice; n=5/group. 
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5.2.4 Differences in COMT protein distribution between MB-COMT and S-COMT 
 
In the brain, MB-COMT accounted for approximately 58% of the total COMT protein (Fig. 
13). Conversely, only ~50% of the total COMT protein could be attributed to MB-COMT in 
the liver (Fig. 13). Even lower percentages of MB-COMT were observed in other peripheral 
tissues (Fig. 13). However, when all of the central and peripheral tissues were pooled 
together, MB-COMT accounted for 50% of the total COMT protein, on average (please refer 
to original publication II for further figures). 
Previous studies provided inconsistent reports regarding the association of MB-COMT with 
the plasma membrane. We utilised S-COMT-deficient mice, which only express MB-COMT, 
and assessed the co-localisation of COMT and a specific plasma membrane marker (Na+/K+ 
ATPase). We revealed that MB-COMT was not attached to the cell membrane but was 
instead most likely attached to cytosolic membranes (please refer to original publication II for 
figures). Furthermore, nuclear COMT-ir was absent in S-COMT-deficient mice. As wild type 
mice exhibited nuclear COMT-ir, these results indicate that only S-COMT, but not MB-
COMT, is present in the nucleus. However, as we did not use a nuclear marker, these findings 
must be judged with caution (please refer to original publication II for figures). 
 
 
Figure 13: COMT protein expression in the brain and peripheral tissues of wild type (Wt) and S-COMT-
deficient (S-COMT -/-) mice; n=5/group. 
 
5.3 Oestrogenic regulation of COMT activity in rats (Study III) 
 
5.3.1 Effect of ovariectomy and drug treatments on body weight 
 
Ovariectomy led to a slight increase in body weight (229.4 ± 9.7 versus 250.8 ± 12.7 g) (Fig. 
14A). However, ovariectomised rats receiving oestradiol (100 µg/kg/day) exhibited stable 
body weights (223.6 ± 6.9 versus 225.4 ± 3.2 g) during the 14-day treatment period (Fig. 
14A). Intact female rats receiving injections of tamoxifen (500 µg/kg/day) displayed a 
significant decrease in body weight (248.0 ± 5.0 versus 240.8 ± 5.6 g) (Fig. 14B). Mirroring 
the findings in female rats, male rats receiving oestradiol (100 µg/kg/day) had stable body 
weights throughout the 14-day treatment period (274.4 ± 5.1 versus 276.2 ± 6.0 g) (Fig. 14C). 
 
 32
5.3.2 Effect of ovariectomy and hormonal treatments on COMT activity 
 
Ovariectomy itself did not affect COMT activity (Fig. 15A-D). Unexpectedly, even 
reintroduction of oestradiol (100 µg/kg for 14 days) to ovariectomised rats failed to alter 
COMT activity (Fig. 15A-D).  
Female rats receiving tamoxifen, a selective oestrogen receptor modulator (SERM), for 14 
days displayed elevated COMT activities in the PFC and kidney. However, no effect of 
tamoxifen treatment was observed in any of the other tissues analysed. Male rats receiving 
oestradiol failed to display any changes in COMT activity. The only exception was the 
striatum, in which COMT activity unexpectedly increased in response to oestradiol (Fig. 
15E).  
 
Figure 14: Body weights of female (A, B) and male (C) Wistar rats during the 14-day experimental period. 
Vehicle groups represent intact female (A, B) and male (C) Wistar rats receiving injections with sesame oil. (A) 
Ovariectomy (OVX) led to a slight increase in body weight (A), whereas  ovariectomized rats receiving 
oestradiol (100 µg/kg/day) exhibited stable body weights (A). Tamoxifen (500 µg/kg/day) treatment of intact 
females led to a decrease in body weight, and this decrease reached statistical significance at day 10 of the 
treatment. Male rats receiving oestradiol (100 µg/kg/day) exhibited markedly decreased body weights from day 
5 onwards (C). Significantly different from vehicle: *p < 0.05, **p < 0.01, ***p < 0.001; n = 5-10 
animals/group. 
 
5.3.3 Effect of ovariectomy and hormonal treatments on COMT protein 
expression 
 
Ovariectomy increased COMT protein expression in the PFC, whereas COMT protein 
expression remained unchanged after reintroduction of oestradiol to ovariectomised rats (Fig. 
16A). 
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Administration of tamoxifen to female rats led to markedly increased COMT protein 
expression in the PFC, hypothalamus, kidney, uterus and ovaries (Fig. 16A-D).  
Oestradiol-treated male rats exhibited a variety of changes in COMT protein expression. 
While COMT protein levels were significantly reduced in the PFC and kidney, they were 
markedly increased in the hippocampus, cerebellum and prostate as a consequence of 
oestradiol administration (Fig. 16E). 
 
 
Figure 15: COMT enzyme activity in brain and peripheral tissues of treated and untreated female and male 
Wistar rats. Female rats received daily s.c. injections of either vehicle (sesame oil), tamoxifen (500 µg/kg/day) 
or oestradiol (100 µg/kg/day) (A-D). Male rats received daily s.c. injections of either vehicle (sesame oil) or 
oestradiol (100 µg/kg/day) (E). Values are expressed as the mean ± SEM; n = 5-10. OVX = ovariectomised; 
OVX + E = ovariectomised + oestradiol. 
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Figure 16: COMT protein expression in brain and peripheral tissues of treated and untreated female and male 
Wistar rats. Female rats received daily s.c. injections of either vehicle (sesame oil), tamoxifen (500 µg/kg/day) 
or oestradiol (100 µg/kg/day) (A-D). Male rats received s.c. injections of either vehicle (sesame oil) or 
oestradiol (100 µg/kg/day) (E). Values are expressed as the mean ± SEM and represent values normalised to the 
values obtained from tissues of intact, vehicle-treated females (A-D) or males (E); n = 5-10. OVX = 
ovariectomised; OVX + E = ovariectomised + oestradiol. 
 
5.4 Effect of low COMT activity on feeding patterns of female 
rodents (Study IV) 
 
5.4.1 Effect of fasting and re-feeding on prefrontal and striatal COMT activities 
 
Overall, the 16-h fasting period did not alter prefrontal and striatal COMT activity in rats and 
mice (Fig. 17A-D). However, we observed a slight (yet not significant) decrease in COMT 
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activity in the PFC and striatum of female C57BL/6 mice (Fig. 17A and B), whereas COMT 
activities in female rats remained unchanged (Fig. 17C and D). 
 
Figure 17: Effect of fasting and re-feeding on prefrontal and striatal COMT activity. Female Wistar rats and 
female C57BL/6 mice were assigned to one of three groups: controls, which had free access to food during the 
entire experiment; starved animals, which were fasted for 16 h; and re-fed animals, which had free access to 
food for 2 h after a 16-h fasting period; all groups had free access to water. Animals were decapitated 
immediately after the 16-h fasting or 2-h re-feeding period, and prefrontal and striatal COMT activities were 
measured; n=6/group. 
 
5.4.2 Effect of acute administration of OR-1139 on feeding patterns in fasted 
female rodents 
 
Administration of the centrally acting COMT inhibitor OR-1139 (3, 10 or 30 mg/kg; i.p.) to 
rats did not affect the latency to initiate the first meal or the total number of meals. However, 
rats receiving OR-1139 (10 mg/kg) spent significantly more time eating than control rats 
during the 4-h observation period. The most striking result, however, was that rats receiving 
OR-1139 (3 and 30 mg/kg) had significantly more long meals (each meal lasting 300 sec or 
more) and significantly fewer short meals (each meal lasting 30 sec or less) than the control 
animals (Fig. 18A).  
In mice, acute COMT inhibition failed to affect the latency to initiate feeding, total time spent 
eating, or total amount of pellets consumed. However, mice receiving OR-1139 (3, 10 and 30 
mg/kg) had significantly fewer short meals than control mice (Fig. 18B).  
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Figure 18: Effect of OR-1139 on feeding patterns of fasted female rodents. Single housed female Wistar rats (A) 
and female C57BL/6 mice (B) were fasted for 16 h prior to the experiment. Rats and mice were injected (i.p.) 
with either OR-1139 (3, 10 or 30 mg/kg) or vehicle (0.5% carboxymethylcellulose gel) immediately before the 
experiment. Rats and mice were then offered previously weighed food pellets. A web camera placed above the 
animal’s cage recorded the first 4 h of re-feeding. The length of the individual meals was calculated, and meals 
were categorised as short meals (30-60 sec), intermediate meals (60-300 sec) and long meals (>300 sec). 
Significantly different from control: *p < 0.05, **p < 0.01, ***p < 0.001; n = 4-6 animals/group. Three 
repetitions of the experiment were performed with each animal. 
 
5.4.3 Effect of COMT gene disruption on feeding patterns in fasted female 
C57BL/6 mice 
 
COMT-deficient (COMT -/-) mice were used as a model to mimic long-term or chronic 
COMT inhibition (as opposed to transiently inhibiting COMT with OR-1139). COMT -/- 
mice exhibited a substantially prolonged delay in initiating the first meal and spent 
significantly less time eating compared with the wild type controls. Furthermore, COMT -/- 
mice persistently ate fewer pellets during the light phase (daytime) of the experiment than 
control mice. However, this difference in total food intake was compensated for during the 
dark phase (night time) of the experiment, and there were no differences in 24-h pellet 
consumption between the genotypes. Unexpectedly, COMT -/- mice did not exhibit the same 
tendency towards longer meals that was observed in animals receiving OR-1139 (Fig. 19). 
 
Figure 19: Effect of COMT gene deletion on feeding patterns 
of fasted female C57BL/6 COMT -/- mice. Single housed 
female C57BL/6 COMT -/- mice were fasted for 16 h prior to 
the experiment. Mice were then offered previously weighed 
food pellets. A web camera placed above the animal’s cage 
recorded the first 4 h of re-feeding. The length of the 
individual meals was calculated, and meals were categorised 
as short meals (30-60 sec), intermediate meals (60-300 sec) 
and long meals (>300 sec); n = 4-6 animals/group. Three 
repetitions of the experiment were performed with each 
              animal. 
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6. Discussion 
 
The purpose of these studies was to elucidate the distribution, regulation and physiological 
roles of COMT. Because of the newly revealed possible relevance of COMT in several 
diseases (e.g., psychiatric diseases involving PFC function) and phenotypes (e.g., pain 
sensitivity), knowledge about the distribution, regulation and physiological role of COMT is 
vital for the development of new drug treatments. 
Our studies revealed that COMT is absent from presynaptic dopaminergic and 
noradrenergic neurons in the rat brain. Furthermore, studies in mice demonstrated that the 
general distribution patterns of MB-COMT and S-COMT throughout the body are rather 
similar. Both COMT isoforms were found in glial cells. Notably, only S-COMT was present 
in the cell nuclei, whereas MB-COMT, contrary to common belief, was not associated with 
the plasma membrane. 
Treatment of rats with oestrogen or tamoxifen confirmed the downregulatory function 
of oestrogen, which had previously only been reported in vitro. However, some tissues 
exhibited increased COMT protein and activity levels after oestrogen exposure, supporting 
reports suggesting that COMT may protect tissues from toxic oestrogen metabolites. 
Finally, we found that decreasing COMT levels (either via the administration of a 
centrally acting COMT inhibitor, OR-1139, or by knocking out the COMT gene) had only a 
minor effect on the rodents’ feeding behaviour. Nevertheless, animals receiving OR-1139 
exhibited different feeding patterns than control animals. Furthermore, COMT activities in 
mice were slightly, but not significantly, decreased after a 16-h starvation period, indicating 
that the importance of COMT may depend on the physiological status. 
 
6.1 COMT protein expression and activity in presynaptic 
dopaminergic and noradrenergic neurons of the rat brain (Study I) 
 
The presence of COMT in presynaptic dopaminergic neurons has been previously 
investigated by Kaakkola and colleagues (1987). However, due to lesioning of the medial 
forebrain bundle, the authors were unable to distinguish between SN and VTA dopaminergic 
neurons. We therefore selectively destroyed dopaminergic neurons originating either from the 
SN or VTA to give a more thorough and detailed analysis of dopaminergic projection areas. 
Despite successful lesioning, as indicated by decreased dopamine levels in several projection 
areas of the SN and VTA, COMT protein and activity levels remained unchanged. Together, 
these results strongly suggest that COMT is not present in presynaptic dopaminergic neurons 
originating from the lateral SN or VTA. 
Several previous studies have addressed the issue of the exact localisation of COMT 
in the brain. A study utilising kainic acid, a toxin that destroys postsynaptic neurons, found 
COMT activity to be decreased, suggesting that COMT is present in postsynaptic terminals of 
the striatum (Rivett et al., 1983). Furthermore, a considerable amount of COMT resides in 
microglial cells. Intrastriatal infusion of fluorocitrate, an astroglial toxin, increases COMT 
immunoreactivity and activity in microglial cells (Reenilä et al., 1997). Accordingly, local 
infusion of LPS, a potent activator of microglial cells, gradually increases microglial COMT 
activity and protein expression over a 14-day period (Helkamaa et al., 2007). As treatment 
with 6-OHDA causes a significant inflammatory response followed by an increased invasion 
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of microglial cells (Cicchetti et al., 2002), changes in neuronal COMT activity and expression 
in our study may have been masked by an increase in microglial COMT. 
In contrast to previous studies, Chen and colleagues report that the catalytic domain of 
MB-COMT is oriented towards the extracellular space (Chen et al., 2011) in human 
lymphoblastoid cells. Furthermore, the authors found that MB-COMT is localised in 
presynaptic as well as postsynaptic neurons in a primary culture of rat cortical neurons, 
challenging the common belief that COMT is absent from presynaptic neurons. Human 
prefrontal COMT activity increases from neonates to adulthood (Tunbridge et al., 2007). The 
increase in COMT activity during postnatal maturation may be, at least in part, due to 
differences in the importance and function of COMT during maturation into adulthood. To 
the best of our knowledge, the cellular localisation of COMT has not been studied during 
different developmental stages. However, based on the increase in COMT activity during 
development, one may assume that the localisation of the COMT enzyme may also vary 
depending on its function during different developmental stages. Chen and colleagues 
examined the localisation of MB-COMT in rats at embryonic day 18. While their findings are 
very interesting, they may not reflect the situation in adult animals. 
Several studies have addressed the question of COMT’s presence in peripheral 
noradrenergic neurons (Crout et al., 1961; Jarrott & Iversen, 1971; Jarrott, 1971). By contrast, 
the presence of COMT in presynaptic noradrenergic neurons in the brain remains uncertain. It 
has been suggested that schizophrenia is associated with noradrenergic neurodegeneration 
and low COMT activity levels. However, a study by Cross and colleagues (1978) that 
compared the post-mortem COMT activities of schizophrenics and control patients failed to 
reveal any differences in COMT activity among these two groups. Accordingly, despite 
successful lesioning of noradrenergic neurons with DSP-4, we did not observe any changes in 
COMT protein or activity levels.  
Although together our results strongly suggest that COMT is not present in presynaptic 
dopaminergic or noradrenergic neurons, the proportion of COMT in these neurons may be 
too small for the biochemical detection methods used in the present study. Therefore, future 
immunohistochemical studies are needed to clarify the presence of COMT in presynaptic 
dopaminergic and noradrenergic neuron populations. 
 
6.2 COMT protein distribution and activity in wild type and S-COMT-
deficient mice (Study II) 
 
Previous studies have demonstrated that COMT is a ubiquitous enzyme that is present 
in virtually all mammalian tissues. However, the relative tissue amounts of MB-COMT and 
S-COMT vary considerably between different species. Furthermore, it has not been possible 
to determine the distinct distribution of MB-COMT and S-COMT because antibodies 
directed against COMT detect both enzyme isoforms. We therefore determined the specific 
distribution and activity of COMT, drawing a detailed picture of the overall distribution and 
activity of COMT in the mouse. Moreover, we utilised S-COMT-deficient mice (completely 
lacking the soluble form of COMT) to further determine the tissue distribution of MB-
COMT. 
We revealed that the overall distribution of COMT among different tissues was 
essentially very similar in wild type and S-COMT-deficient mice. COMT was present in all 
of the analysed tissues, and the liver and kidneys exhibited the highest amounts of COMT 
 39
protein and activity in both genotypes. These findings are in line with previous studies 
reporting high levels of COMT in the kidney and liver (for review see Männistö & Kaakkola, 
1999). In comparison, the brain contained only relatively low COMT protein and activity 
levels. The highest amounts of both were measured from the striatum and PFC. Generally, 
COMT plays only a subordinate role in dopamine metabolism. However, the PFC constitutes 
an exception to this rule. Because the PFC contains only low levels of dopamine transporters, 
COMT dominates in the regulation of dopamine levels in this area (Yavich et al., 2007; 
Käenmäki et al., 2010). In agreement with our data, Matsumoto and colleagues (2003) found 
that, in humans and rats, COMT mRNA levels are highest in the PFC. Accordingly, a high-
throughput mRNA screening study found that COMT mRNA levels are highest in the PFC in 
human, rat and mouse brains (Su et al., 2002). Notably, our COMT immunohistochemical 
results were in disagreement with our findings from COMT western blot analysis, indicating 
that COMT is only moderately present in the PFC. This apparent contradiction may arise 
from methodological aspects. In the immunohistochemical analysis, the entire brain was cut 
into sections, and optical densities were subsequently measured (with imaging software) from 
selected brain sections representing the PFC. The pitfall of this method is that only a couple 
of representative brain sections (but not the entire PFC) were analysed. Therefore, the overall 
amount of COMT may easily have been over- or underestimated. By contrast, in western blot 
analysis, the entire PFC was homogenised, and the two COMT bands were detected by 
chemiluminescence. Western blot analysis therefore provides a more reliable quantification, 
especially when analysing larger areas like the PFC. 
Because MB-COMT and S-COMT differ in their kinetic constants, the relative contribution 
of each isoform to overall O-methylation is dependent on the concentration of the catechol 
substrate (with the exception of catechol oestrogens, for which both COMT isoforms have 
similar affinities). At low concentrations of catecholamines, O-methylation by MB-COMT 
(low Km value) predominates, and only when the substrate concentration is raised above 
saturation will the contribution of S-COMT (high Km value) increase and eventually prevail. 
It is therefore commonly assumed that MB-COMT is the functionally more important form of 
COMT in the brain (Rivett et al., 1982; Roth, 1992), whereas S-COMT is considered to 
predominate in the elimination of biologically active/toxic catechols (Lotta et al., 1995; 
Männistö & Kaakkola, 1999). Accordingly, in our study, S-COMT was generally 
predominant in peripheral tissues, whereas MB-COMT prevailed in the brain. It has been 
reported that, in the absence of S-COMT (S-COMT-deficient mice), MB-COMT seems to 
readily assume the function of S-COMT in the periphery and tissue-dependently accounts for 
approximately 25-50% of the COMT activity found in wild type mice (Käenmäki et al., 
2009). Accordingly, we found that MB-COMT in S-COMT deficient mice accounted for 
approximately 25 (periphery) to 50% (CNS), on average, of the COMT activity found in wild 
type mice. However, the contribution of S-COMT and MB-COMT to the O-methylation of 
different substrates may depend not only on the kinetic properties of the enzymes but also on 
the intracellular distributions of the substrates. Both COMT isoforms are intracellular 
enzymes; MB-COMT is attached to the rough endoplasmic reticulum and mitochondrial 
membranes, whereas S-COMT is mainly cytoplasmic and, to some extent, nuclear. Early 
immunohistochemical studies claimed that COMT is present in glial cells but not neurons 
(Kaplan et al. 1979). Subsequently, COMT-immunoreactivity was also detected from 
neuronal cells (Karhunen et al., 1995; Brisch et al., 2009). Our study detected COMT in some 
distinct short neurons and astroglial cells, however, the majority of COMT was associated 
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with microglial cells. Previous studies report that COMT-ir increases in glial cells after 
insults (Reenilä et al., 1997; Helkamaa et al., 2007), suggesting that COMT may play an 
important role in acute immune defence. Notably, nuclear COMT-ir was absent in S-COMT-
deficient mice, indicating that MB-COMT is not present in cell nuclei. Furthermore, MB-
COMT did not colocalise with cell membranes directly but instead may be associated with 
cytosolic membranes, supporting earlier findings by Ulmanen and colleagues (1997). 
 
6.3 Complex oestrogenic regulation of COMT in rats (Study III) 
 
Previous studies reporting lower COMT activity in women than in men and variations 
in COMT activity during the oestrus cycle in animals suggest that the regulation of the 
COMT gene is hormone-sensitive (Parvez et al., 1978; Boudikova et al., 1990). In 1999, Xie 
and colleagues identified two oestrogen response elements on the COMT promoter gene and 
demonstrated that COMT mRNA levels are downregulated in response to oestradiol in cells 
expressing ERs (but not in cells that do not express ERs). Subsequently, Jiang et al. (2003) 
showed that this oestrogenic downregulation of the COMT gene is accompanied by a 
decrease in COMT activity and protein levels. In line with the aforementioned reports, our 
study revealed that antagonising/modulating the effects of oestrogen by means of 
ovariectomy or treatment with tamoxifen increases COMT activity and protein expression in 
several central and peripheral tissues. Although tamoxifen was originally developed as an 
anti-oestrogen, it was later termed a SERM because of its tissue-selective oestrogenic 
activity. However, in our study, tamoxifen mimicked the effects of ovariectomy in the PFC, 
indicating that tamoxifen exerts anti-oestrogenic activity in this brain area. Accordingly, 
tamoxifen increased prefrontal COMT protein expression and activity, presumably by 
antagonising the effects of oestradiol. Furthermore, the uterus and ovaries were particularly 
responsive to the effects of tamoxifen. In line with previous findings, tamoxifen caused a 
significant decrease in uterine (Wakeling & Bowler, 1988; Carthew et al., 1996; Beland et al., 
1999; Ickenstein & Bandiera, 2002) and ovarian weight (Ickenstein & Bandiera, 2002), 
indicative of anti-oestrogenic activity. Accordingly, COMT protein amounts were 
significantly increased in both tissues, once more confirming the downregulatory effect of 
oestrogen on COMT. In intact male Wistar rats, amplifying the effects of oestradiol with 
daily injections of oestradiol decreased COMT protein expression in the PFC and kidneys, 
complementing our observations in female rats. However, oestradiol unexpectedly led to an 
increase in COMT activity and protein expression in several tissues. The prostate seemed 
particularly responsive, and COMT protein levels increased 2-fold following oestradiol 
treatment. As there is some evidence suggesting that oestrogen can initiate prostate cancer via 
its reactive catechol metabolites (Bosland, 2000; Cavalieri et al., 2002), the observed increase 
in COMT protein (which metabolizes catechol oestrogens) may represent a compensatory 
mechanism to protect the prostate (and other tissues) from developing cancer. The variability 
in tissue responses to our treatments may be at least partially due to the different distribution 
patterns of ERs. Although both ER alpha (ERα) and ER beta (ERβ) are capable of activating 
transcription in response to oestradiol, ERα is substantially more efficient in activating 
transcription than ERβ (Harris et al., 2001). Furthermore, several studies suggest that the 
differential pharmacology of tamoxifen is due to differences in coactivator/corepressor 
availability in different tissues (McDonnell et al., 2002; Smith & O'Malley, 2004). Finally, 
several brain areas have been reported to be sexually dimorphic, meaning that they may 
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respond differently to hormonal interventions in male and female rats (Gillies & McArthur, 
2010).  
 
6.4 Effect of low COMT activity on feeding patterns of female 
rodents (Study IV) 
 
Dopamine is usually released in a slow and irregular fashion. However, salient 
environmental stimuli (e.g., food) elicit a transient increase in dopamine levels and allow the 
animal to focus on the food reward (Overton & Clark, 1997). This transient increase in 
synaptic dopamine levels can then lead the animal to focus its attention on the relevant 
environmental stimuli (in this case the food reward), while ignoring irrelevant stimuli 
(Overton & Clark, 1997; Palmiter, 2007). Recently, Lapish and colleagues (2009) 
demonstrated that tolcapone, a centrally acting COMT inhibitor, is able to significantly 
enhance prefrontal dopamine levels in rats during food anticipation and also during actual 
food consumption. A study by Peciña and colleagues (2003) proposes that increased synaptic 
dopamine levels lead to increased ''wanting'' of (sweet) rewards and enables animals to 
''focus'' more strongly on the food reward. Together, the aforementioned reports suggest a 
possible role for prefrontal dopamine in feeding behaviour.  
Based on the particular importance of COMT in the metabolism of prefrontal 
dopamine, one could assume that a change in COMT activity may influence feeding 
behaviour. Indeed, our study revealed that the manipulation of COMT activity affects some 
of the feeding parameters of female rodents. However, the manner in which COMT is 
controlled seems to determine the direction in which the feeding behaviour is changed. 
Transiently inhibiting COMT via the application of a centrally acting COMT inhibitor (OR-
1139) led both rats and mice to consume more ''long'' meals (each meal lasting 300 sec or 
more) and fewer short meals (each meal lasting 30 sec or less) than their vehicle-treated 
peers. Unexpectedly, these results were not reproducible in COMT -/- mice, which 
completely lack the COMT enzyme from birth. These differences may be due to multiple 
reasons, e.g., developmental alterations in knockout mice, non-identical effects of fasting in 
rats, mice and COMT -/- mice and the slightly different ages of the animals. Furthermore, 
female COMT -/- mice exhibit increased anxiety levels in a number of behavioural tests. For 
example, they display an exaggerated response to stress-induced hyperthermia and acoustic 
startle (Papaleo et al., 2008), demonstrate altered emotional reactivity in the dark/light 
exploratory model (Gogos et al., 1998) and present higher levels of anxiety when evaluated in 
the elevated plus maze paradigm (Papaleo et al., 2008). Our observation that COMT -/- mice 
appeared to be more alert and anxious overall than wild type mice and exhibited long periods 
of sniffing and rearing before initiating the first meal is in line with the aforementioned 
studies. 
However, animals treated with OR-1139 may have experienced enhanced prefrontal 
dopamine levels, which then led them to consume longer meals than vehicle-treated animals. 
Accordingly, animals receiving OR-1139 seemed to concentrate more on the food reward and 
were less easily distracted from their meals than their vehicle-treated peers. Together, these 
behavioural differences may well be the result of an increased ''desire'' for the food reward, 
likely caused by an enhanced dopaminergic tone. 
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7. Conclusions 
 
The aim of this study was to gain new insights into the distribution, regulation and 
physiological role of COMT. The principal results can be summarised as follows: 
 
1. Selective lesions of presynaptic dopaminergic and noradrenergic neurons failed to alter 
COMT protein and activity levels in rats. These findings strongly suggest the absence of 
COMT in these neurons. Nevertheless, it is possible that the proportion of COMT in the 
lesioned neurons is too small for biochemical detection. Therefore, future 
immunohistochemical studies are needed to clarify the presence of COMT in presynaptic 
dopaminergic and noradrenergic neuron populations. 
 
2. The general distribution patterns of S-COMT and MB-COMT were similar in mice. Both 
COMT isoforms were associated with microglial cells in the brain. Furthermore, astroglial 
cells, pyramidal neurons, cerebellar Purkinje and granular cells and striatal spiny neurons also 
contained both COMT isoforms. Nevertheless, only S-COMT was present in the cell nuclei. 
Furthermore, MB-COMT was not associated with the plasma membrane as previously 
assumed but instead may be attached to intracellular cytosolic membranes.  
 
3. Antagonising or modulating the effects of oestrogen via administration of the selective 
oestrogen receptor modulator tamoxifen increased COMT activity and expression in several 
tissues of female Wistar rats. Notably, the PFC and kidney were most convincingly regulated 
by oestrogen state. Furthermore, increasing oestradiol levels in male rats led to a 
compensatory upregulation of COMT in several tissues, underlining the importance of 
COMT in the clearance of biologically active oestrogen metabolites. Together these findings 
confirm previous in vitro studies demonstrating that COMT is regulated by oestrogen. 
 
4. Acute COMT inhibition did not change the overall food consumption of female rodents. 
However, the feeding pattern was affected, and animals receiving a COMT inhibitor had 
significantly fewer short meals and more ''long'' meals than their vehicle-treated peers. 
Furthermore, starvation induced a slight, albeit not significant, decrease in prefrontal and 
striatal COMT activity in mice, indicating that the importance of COMT may vary depending 
on the physiological status. 
 
In conclusion, MB-COMT and S-COMT show similar distribution patterns and their absence 
from presynaptic dopaminergic and noradrenergic neuron terminals suggests a secondary 
(and perhaps more modulatory) role of COMT in neurotransmitter metabolism in the brain. 
The observation that oestrogens exert a regulatory function on COMT in vivo and may even 
lead to a compensatory upregulation of the COMT protein may be of clinical importance, as 
COMT inhibitors are used in the treatment of PD. Lastly, the observed decrease in COMT 
activity after a relatively short starvation period may hint at a ''hidden'' role of COMT during 
different physiological states. Therefore, although COMT inhibition does not alter 
catecholamine levels under basal conditions, COMT may increase in importance during 
certain physiological and pathological conditions. 
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